JP2002060786A - Germicidal stainproofing agent for hard surface - Google Patents

Germicidal stainproofing agent for hard surface

Info

Publication number
JP2002060786A
JP2002060786A JP2000252284A JP2000252284A JP2002060786A JP 2002060786 A JP2002060786 A JP 2002060786A JP 2000252284 A JP2000252284 A JP 2000252284A JP 2000252284 A JP2000252284 A JP 2000252284A JP 2002060786 A JP2002060786 A JP 2002060786A
Authority
JP
Japan
Prior art keywords
group
carbon atoms
weight
alkyl
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000252284A
Other languages
Japanese (ja)
Inventor
Shin Aihara
伸 相原
Noriyuki Morii
紀行 森井
Kazukuni Tsukuda
一訓 佃
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kao Corp
Original Assignee
Kao Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kao Corp filed Critical Kao Corp
Priority to JP2000252284A priority Critical patent/JP2002060786A/en
Priority to PCT/JP2001/006869 priority patent/WO2002016536A1/en
Priority to TW90120399A priority patent/TWI283267B/en
Publication of JP2002060786A publication Critical patent/JP2002060786A/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C11ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11DDETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/48Medical, disinfecting agents, disinfecting, antibacterial, germicidal or antimicrobial compositions
    • CCHEMISTRY; METALLURGY
    • C11ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11DDETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D1/00Detergent compositions based essentially on surface-active compounds; Use of these compounds as a detergent
    • C11D1/38Cationic compounds
    • C11D1/62Quaternary ammonium compounds
    • CCHEMISTRY; METALLURGY
    • C11ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11DDETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16Organic compounds
    • C11D3/37Polymers
    • C11D3/3746Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • C11D3/3769(Co)polymerised monomers containing nitrogen, e.g. carbonamides, nitriles or amines

Abstract

PROBLEM TO BE SOLVED: To obtain a germicidal stain-proofing agent usable in the home, capable of providing hard surfaces around the circumference of a toilet, a bathroom, a kitchen, etc., with both excellent antimicrobial properties and soil resistance. SOLUTION: This germicidal strain-proofing agent for a hard surface comprises (a) a polymer which has 1,000-6,000,000 weight-average molecular weight and 10-100 mol% ratio of a quaternary ammonium group-containing monomer unit to the whole monomer units and (b) a quaternary ammonium group-containing antimicrobial compound having <1,000 molecular weight.

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[0001]

【発明の属する技術分野】本発明は、硬質表面の殺菌、
及び防汚性、すなわち汚れの付着の防止、及び付着した
汚れを容易に除去することを可能にする硬質表面用の殺
菌防汚剤に関し、住居内全般、特に台所や浴室、トイ
レ、洗面台などの、壁や床、器具、機器などに使用した
際に、殺菌並びに汚れの付着防止及び易洗浄を可能にす
る硬表面用殺菌防汚剤に関する。
The present invention relates to sterilization of hard surfaces,
And anti-fouling property, that is, a bactericidal anti-fouling agent for hard surfaces that enables the prevention of the adhesion of dirt and the easy removal of the adhering dirt, in general in a house, especially kitchens, bathrooms, toilets, wash basins, etc. The present invention relates to a bactericidal and antifouling agent for hard surfaces which can be used for walls, floors, appliances, equipment, etc., and which can sterilize, prevent the adhesion of dirt, and easily clean.

【0002】[0002]

【従来の技術及び発明が解決しようとする課題】生活場
面では様々な場所で汚れが発生する。それらの汚れを除
去するために各種の洗浄剤が開発され、その洗浄力を強
化すべく検討がなされてきた。これら努力により、頑固
な汚れを落とすための手段が多く提案されている。
2. Description of the Related Art Dirt is generated in various places in a living scene. Various cleaning agents have been developed to remove such stains, and studies have been made to enhance their cleaning power. With these efforts, many means for removing stubborn dirt have been proposed.

【0003】また、このように汚れの除去性に優れた洗
浄剤を開発する一方で、汚れを付きにくくする技術及び
処理を施すことで付いた汚れを落とし易くする技術(以
後防汚性とする)に関する技術も多く検討されており、
洗浄剤として応用する技術が見出されている。例えば、
特開平2−145697号公報には、特定構造のスルホ
ベタイン型両性界面活性剤を配合する水洗トイレ用清浄
剤が、特開平3−35097号公報には、スルホコハク
酸ジエステルを含有する軟便付着防止性に優れ洗浄効果
の高い水性トイレ用清浄剤が、特開平10−1697号
公報には、特定の界面活性剤と水溶性溶剤を特定比率で
配合する洗浄剤が記載されている。特に、特開平9−1
69995号公報には、処理後の硬質表面に対する水の
接触角が30度以下となるような洗浄剤が優れた防汚性
を示し、具体的に、防汚基剤として、アニオン界面活性
剤と分子中に4級アンモニウム基を含む界面活性剤又は
水溶性ポリマーとの組み合わせが挙げられている。
[0003] In addition, while developing such a cleaning agent excellent in dirt removal properties, a technique for making dirt less likely to adhere and a technique for easily removing dirt attached by performing treatment (hereinafter referred to as antifouling property). ) Technologies are also being considered,
Techniques for application as cleaning agents have been found. For example,
JP-A-2-14597 discloses a flush toilet detergent containing a sulfobetaine-type amphoteric surfactant having a specific structure, and JP-A-3-35097 discloses a soft fecal adhesion-preventing agent containing a sulfosuccinic diester. Japanese Unexamined Patent Publication No. 10-1697 discloses a cleaning agent which is excellent in cleaning effect and has a high cleaning effect, in which a specific surfactant and a water-soluble solvent are mixed at a specific ratio. In particular, Japanese Patent Laid-Open No. 9-1
No. 69,995 discloses that a detergent having a water contact angle of 30 ° or less with a hard surface after treatment exhibits excellent antifouling property. Specifically, an anionic surfactant is used as an antifouling base. A combination with a surfactant containing a quaternary ammonium group in the molecule or a water-soluble polymer is mentioned.

【0004】以上のように、従来から防汚性に関する技
術は多く検討されてきている。しかしながら、従来の技
術は、水垢や便等の付着による汚れの発生を中心に抑制
するものであり、微生物やカビ由来の黒ずみに関する汚
れについては不十分である。加えて最近では、生活環境
の改善にともなって、目に見える汚れに加えて、衛生面
での問題を懸念する人が増えてきており、殺菌に対する
要求も高まってきている。
As described above, many techniques relating to antifouling properties have been studied. However, the conventional technology mainly suppresses the generation of stains due to adhesion of water scales and faeces, and is insufficient for stains related to darkening caused by microorganisms and mold. In addition, recently, with the improvement of the living environment, more and more people are concerned about hygiene problems in addition to visible stains, and the demand for sterilization is increasing.

【0005】このような殺菌に関する考え方として殺菌
剤の配合が提案される。しかしながら、家庭用に使用す
ることが一般的である殺菌剤を前記防汚剤に配合した場
合、防汚性と殺菌性の両方の効果を相殺してしまい、満
足できる殺菌性及び防汚性を達成することは極めて困難
であった。
[0005] As a concept regarding such sterilization, blending of a fungicide is proposed. However, when a disinfectant commonly used for home use is added to the antifouling agent, the effects of both the antifouling property and the bactericidal property are offset, and satisfactory bactericidal and antifouling properties are obtained. It was extremely difficult to achieve.

【0006】本発明の課題は、家庭で使用でき、トイ
レ、浴室、台所まわりなどの硬質表面に対し、殺菌性と
防汚性の両方を満足できる水準で付与できる剤を提供す
ることにある。
An object of the present invention is to provide an agent which can be used at home and which can impart both sterilizing and antifouling properties to hard surfaces such as toilets, bathrooms and kitchens at a satisfactory level.

【0007】[0007]

【課題を解決するための手段】本発明は、(a)重量平
均分子量が1,000〜6,000,000であって、
4級アンモニウム基を有するモノマー単位の比率が全モ
ノマー単位に対して10〜100モル%である重合体
〔以下、(a)成分という〕、及び(b)分子量が1,
000未満であって、4級アンモニウム基を有する殺菌
性化合物〔以下、(b)成分という〕を含有する硬質表
面用殺菌防汚剤に関する。ここで、殺菌とは抗菌の意味
も含むものとする。またモノマー単位とは、重合体を構
成しているモノマー由来のくり返し単位を指し、モノマ
ーとは重合体を作るもとになる低分子物質を指す。
According to the present invention, there is provided (a) a polymer having a weight average molecular weight of 1,000 to 6,000,000,
A polymer in which the ratio of the monomer unit having a quaternary ammonium group is 10 to 100 mol% based on all monomer units (hereinafter, referred to as component (a)), and (b) a molecular weight of 1,
The present invention relates to a bactericidal antifouling agent for hard surfaces containing a bactericidal compound having a quaternary ammonium group of less than 000 [hereinafter referred to as the component (b)]. Here, sterilization includes the meaning of antibacterial. Further, the monomer unit refers to a repeating unit derived from a monomer constituting the polymer, and the monomer refers to a low molecular substance from which the polymer is formed.

【0008】[0008]

【発明の実施の形態】本発明の(a)成分は、4級アン
モニウム基を有するモノマー単位(以下、モノマー単位
Aとする)を10〜100モル%含有する重合体であ
る。
BEST MODE FOR CARRYING OUT THE INVENTION The component (a) of the present invention is a polymer containing 10 to 100 mol% of a monomer unit having a quaternary ammonium group (hereinafter, referred to as monomer unit A).

【0009】モノマー単位Aは、4級アンモニウム基
(複数であってもよい)を含有するモノマー(以下、モ
ノマーAとする)を重合するか又は3級アミノ基(複数
であってもよい)を含有するモノマー(以下、モノマー
A’とする)を重合して得られるモノマー単位を4級ア
ンモニウム化することで得られる。
The monomer unit A is obtained by polymerizing a monomer containing a quaternary ammonium group (which may be plural) (hereinafter, referred to as monomer A) or by forming a tertiary amino group (which may be plural). It is obtained by subjecting a monomer unit obtained by polymerizing a contained monomer (hereinafter, referred to as monomer A ′) to quaternary ammonium.

【0010】モノマーAの好ましい例として、下記一般
式(4)の化合物を挙げることができる。
Preferred examples of the monomer A include a compound represented by the following general formula (4).

【0011】[0011]

【化3】 Embedded image

【0012】〔式中、R12、R13、R14は、それぞれ独
立して、水素原子、水酸基又は炭素数1〜3のアルキル
基である。Xは炭素数1〜12のアルキレン基、−CO
OR18−、−CONHR18−、−OCOR18−、−R19
−OCO−R18−から選ばれる基である。ここでR18
19は、それぞれ独立して、炭素数1〜5のアルキレン
基である。R15は炭素数1〜3のアルキル基もしくはヒ
ドロキシアルキル基又はR1213C=C(R14)−X−で
ある。R16は炭素数1〜3のアルキル基、ヒドロキシア
ルキル基、ベンジル基であり、R17はヒドロキシ基、カ
ルボキシル基、スルホン酸基もしくは硫酸エステル基で
置換されていてもよい炭素数1〜10のアルキル基又は
ベンジル基であり、R17がアルキル基、ヒドロキシアル
キル基又はベンジル基の場合は、Y-は陰イオンを示
す。また、R17がカルボキシル基、スルホン酸基、硫酸
エステル基を含む場合、Y-は存在せず、R17中のこれ
らの基は陰イオンとなる。Y-の陰イオンとしては、ハ
ロゲンイオン、硫酸イオン、炭素数1〜3のアルキル硫
酸エステルイオン、炭素数1〜3のアルキル基で置換さ
れていてもよい芳香族スルホン酸イオン、ヒドロキシイ
オンを挙げることができる。〕。
Wherein R 12 , R 13 and R 14 are each independently a hydrogen atom, a hydroxyl group or an alkyl group having 1 to 3 carbon atoms. X is an alkylene group having 1 to 12 carbon atoms, -CO
OR 18 -, - CONHR 18 - , - OCOR 18 -, - R 19
It is a group selected from —OCO—R 18 —. Where R 18 ,
R 19 is each independently an alkylene group having 1 to 5 carbon atoms. R 15 is an alkyl group or hydroxyalkyl group having 1 to 3 carbon atoms or R 12 R 13 C = C (R 14 ) —X—. R 16 is an alkyl group having 1 to 3 carbon atoms, a hydroxyalkyl group, or a benzyl group; and R 17 has 1 to 10 carbon atoms which may be substituted with a hydroxy group, a carboxyl group, a sulfonic acid group or a sulfate group. When R 17 is an alkyl group, a hydroxyalkyl group or a benzyl group, Y represents an anion. When R 17 contains a carboxyl group, a sulfonic acid group, or a sulfate group, Y does not exist, and these groups in R 17 become anions. Examples of the anion of Y include a halogen ion, a sulfate ion, an alkyl sulfate ion having 1 to 3 carbon atoms, an aromatic sulfonate ion optionally substituted by an alkyl group having 1 to 3 carbon atoms, and a hydroxy ion. be able to. ].

【0013】これらの中でもアクリロイル(又はメタク
リロイル)アミノアルキル(炭素数1〜5)−N,N,
N−トリアルキル(炭素数1〜3)4級アンモニウム
塩、アクリロイル(又はメタクリロイル)オキシアルキ
ル(炭素数1〜5)−N,N,N−トリアルキル(炭素
数1〜3)4級アンモニウム塩、N−(ω−アルケニル
(炭素数3〜10))−N,N,N−トリアルキル(炭
素数1〜3)4級アンモニウム塩、N,N−ジ(ω−ア
ルケニル(炭素数3〜10))−N,N−ジアルキル
(炭素数1〜3)4級アンモニウム塩が好ましく、特に
ジアリルジメチルアンモニウム塩が良好である。
Among them, acryloyl (or methacryloyl) aminoalkyl (C1-5) -N, N,
N-trialkyl (C1-3) quaternary ammonium salt, acryloyl (or methacryloyl) oxyalkyl (C1-5) -N, N, N-trialkyl (C1-3) quaternary ammonium salt , N- (ω-alkenyl (3 to 10 carbon atoms))-N, N, N-trialkyl (1 to 3 carbon atoms) quaternary ammonium salt, N, N-di (ω-alkenyl (3 to 10 carbon atoms) 10)) -N, N-dialkyl (C1-3) quaternary ammonium salts are preferred, and diallyldimethylammonium salts are particularly preferred.

【0014】モノマーA’の好ましい例として、下記一
般式(4’)の化合物を挙げることができる。
Preferred examples of the monomer A 'include a compound represented by the following general formula (4').

【0015】[0015]

【化4】 Embedded image

【0016】〔式中、R12、R13、R14、R15及びR16
は、前記記載と同じ。〕これらの中でもN,N−ジアル
キル(炭素数1〜3)アミノアルキル(炭素数1〜5)
アクリレート(又はメタクリレート)、N,N−ジアル
キル(炭素数1〜3)アミノアルキル(炭素数1〜5)
アクリルアミド、N,N−ジ(ω−アルケニル(炭素数
3〜10))−N−メチルアミンが好ましく、ジアリル
メチルアミンが特に好ましい。
Wherein R 12 , R 13 , R 14 , R 15 and R 16
Is the same as described above. Among them, N, N-dialkyl (C1-3) aminoalkyl (C1-5)
Acrylate (or methacrylate), N, N-dialkyl (C1-3) aminoalkyl (C1-5)
Acrylamide and N, N-di (ω-alkenyl (3 to 10 carbon atoms))-N-methylamine are preferred, and diallylmethylamine is particularly preferred.

【0017】モノマーA’を4級アンモニウム化する際
に用いられる4級化剤としては、メチルクロリド、メチ
ルブロミド、ベンジルクロリド、ジメチル硫酸、ジエチ
ル硫酸、モノクロロ酢酸又はその塩、クロルスルホン酸
又はその塩、3−クロロ−2−ヒドロキシプロパンスル
ホン酸又はその塩、エチレンオキシド、プロピレンオキ
シド、グリシジルエーテルなどを挙げることができる。
尚、エチレンオキシド、プロピレンオキシド、グリシジ
ルエーテルを使用する場合は、予め硫酸、塩酸、炭素数
1〜12のカルボン酸、アリルスルホン酸などでモノマ
ー単位を中和した後反応させることが好ましい。
The quaternizing agent used for converting the monomer A 'into a quaternary ammonium includes methyl chloride, methyl bromide, benzyl chloride, dimethyl sulfate, diethyl sulfate, monochloroacetic acid or a salt thereof, chlorosulfonic acid or a salt thereof. , 3-chloro-2-hydroxypropanesulfonic acid or a salt thereof, ethylene oxide, propylene oxide, glycidyl ether and the like.
When ethylene oxide, propylene oxide, or glycidyl ether is used, it is preferable that the monomer unit is neutralized with sulfuric acid, hydrochloric acid, a carboxylic acid having 1 to 12 carbon atoms, allylsulfonic acid, or the like before the reaction.

【0018】本発明の(a)成分は、モノマー単位A
(複数種であってもよい)からなる重合体のみならず、
モノマー単位A(複数種であってもよい)と他のモノマ
ー単位(以下、モノマー単位Bとする)とから構成され
た重合体であってもよい。(モノマーA’を使用する場
合は、アミン型のモノマー単位を有していてもよい。)
この場合、モノマー単位Aとモノマー単位B(複数種で
あってもよい)との配列様式は、ブロック、交互、周
期、統計(ランダムを含む)、グラフト型の何れであっ
てもよい。
The component (a) of the present invention comprises a monomer unit A
(May be plural kinds),
It may be a polymer composed of a monomer unit A (which may be plural kinds) and another monomer unit (hereinafter, referred to as a monomer unit B). (When the monomer A 'is used, it may have an amine type monomer unit.)
In this case, the arrangement of the monomer unit A and the monomer unit B (there may be plural types) may be any of block, alternating, periodic, statistical (including random), and graft type.

【0019】モノマー単位Aとモノマー単位Bとから構
成される重合体は、例えば、それぞれの前駆体モノマー
を共重合することによって得ることができる。この場
合、モノマー単位Bとしては、下記のモノマー群(i)
〜(v)から選ばれるモノマー由来のモノマー単位が好
ましく、(i)〜(iii)又は(v)記載のモノマー由
来のモノマー単位がより好ましく、特に防汚効果の点か
ら(i)、(ii)又は(v)のモノマー由来のモノマー
単位が最も好ましい。 (i)アクリル酸又はその塩、メタクリル酸又はその
塩、マレイン酸又はその塩、無水マレイン酸、スチレン
スルホン酸塩、スルホプロピルメタクリレート、2−ア
クリルアミド−2−メチルプロパンスルホン酸またはそ
の塩、リン酸モノ−ω−メタクリロイルオキシアルキル
(炭素数1〜12)から選ばれる陰イオン基含有化合物 (ii)アクリルアミド、N,N−ジメチルアミノプロピ
ルアクリル酸(又はメタクリル酸)アミド、N,N−ジ
メチルアクリル(又はメタクリル)アミド、N,N−ジ
メチルアミノエチルアクリル酸(又はメタクリル酸)ア
ミド、N,N−ジメチルアミノエチルアクリル酸(又は
メタクリル酸)アミド、N−ビニル−2−カプロラクタ
ム、N−ビニル−2−ピロリドンから選ばれるアミド基
含有化合物 (iii)アクリル酸(又はメタクリル酸)アルキル(炭
素数1〜5)、アクリル酸(又はメタクリル酸)2−ヒ
ドロキシエチル、アクリル酸(又はメタクリル酸)−
N,N−ジメチルアミノアルキル(炭素数1〜5)、酢
酸ビニルから選ばれるエステル基含有化合物 (iv)エチレン、プロピレン、N−ブチレン、イソブチ
レン、N−ペンテン、イソプレン、2−メチル−1−ブ
テン、N−ヘキセン、2−メチル−1−ペンテン、3−
メチル−1−ペンテン、4−メチル−1−ペンテン、2
−エチル−1−ブテン、スチレン、ビニルトルエン、α
−メチルスチレン、アリルアミン、N,N−ジアリルア
ミン、N,N−ジアリル−N−アルキル(炭素数1〜
5)アミン、エチレンオキシド、プロピレンオキシド、
2−ビニルピリジン、4−ビニルピリジンから選ばれる
化合物 (v)二酸化硫黄。
The polymer composed of the monomer units A and B can be obtained, for example, by copolymerizing the respective precursor monomers. In this case, as the monomer unit B, the following monomer group (i)
To (v) are preferred, and monomer units derived from the monomers described in (i) to (iii) or (v) are more preferred, and (i) and (ii) are particularly preferred from the viewpoint of antifouling effect. ) Or a monomer unit derived from the monomer (v) is most preferred. (I) acrylic acid or a salt thereof, methacrylic acid or a salt thereof, maleic acid or a salt thereof, maleic anhydride, styrene sulfonate, sulfopropyl methacrylate, 2-acrylamido-2-methylpropanesulfonic acid or a salt thereof, phosphoric acid Anionic group-containing compound selected from mono-ω-methacryloyloxyalkyl (C 1 to C 12) (ii) acrylamide, N, N-dimethylaminopropylacrylic acid (or methacrylic acid) amide, N, N-dimethylacryl ( Or methacryl) amide, N, N-dimethylaminoethylacrylic acid (or methacrylic acid) amide, N, N-dimethylaminoethylacrylic acid (or methacrylic acid) amide, N-vinyl-2-caprolactam, N-vinyl-2 -An amide group-containing compound selected from pyrrolidone (iii) Acrylic acid (or methacrylic acid) alkyl (C1-5), acrylic acid (or methacrylic acid) of 2-hydroxyethyl, acrylic acid (or methacrylic acid) -
An ester group-containing compound selected from N, N-dimethylaminoalkyl (1-5 carbon atoms) and vinyl acetate. (Iv) Ethylene, propylene, N-butylene, isobutylene, N-pentene, isoprene, 2-methyl-1-butene , N-hexene, 2-methyl-1-pentene, 3-
Methyl-1-pentene, 4-methyl-1-pentene, 2
-Ethyl-1-butene, styrene, vinyltoluene, α
-Methylstyrene, allylamine, N, N-diallylamine, N, N-diallyl-N-alkyl (having 1 to 1 carbon atoms)
5) amines, ethylene oxide, propylene oxide,
Compounds selected from 2-vinylpyridine and 4-vinylpyridine (v) Sulfur dioxide.

【0020】モノマー単位Aとモノマー単位Bを有する
重合体は前記のような共重合による合成方法の他、モノ
マー単位Aを含む重合体に前記(i)〜(iv)のモノマ
ー、特に好ましくは前記(i)、(ii)のモノマーをグ
ラフト重合して得てもよいし、前記(i)〜(iv)のモ
ノマーを含む重合体、特に好ましくは前記(i)、(i
i)のモノマーを含む重合体に前記一般式(4)のモノ
マーをグラフト重合して得てもよいし、前記(i)〜
(iv)のモノマーを含む重合体、特に好ましくは前記
(i)、(ii)のモノマーを含む重合体に前記一般式
(4’)のモノマーをグラフト重合した後、これを4級
化してもよい。
The polymer having the monomer unit A and the monomer unit B can be synthesized by the above-mentioned copolymerization method. Alternatively, the polymer containing the monomer unit A can be added to the monomers (i) to (iv), particularly preferably The polymer may be obtained by graft polymerization of the monomers (i) and (ii), or a polymer containing the monomers (i) to (iv), and particularly preferably the polymers (i) and (i).
The polymer containing the monomer of i) may be obtained by graft polymerization of the monomer of the general formula (4),
After graft-polymerizing the monomer of the general formula (4 ′) onto the polymer containing the monomer of (iv), particularly preferably the polymer containing the monomer of (i) or (ii), it is quaternized. Good.

【0021】本発明の(a)成分を構成する重合体はい
かなる重合法によって得てもよいが、ラジカル重合法が
特に好ましく、塊状、溶液、又は乳化系にてこれを行う
ことができる。ラジカル重合は加熱によりこれを開始し
てもよいが、開始剤として、2,2’−アゾビス(2−
アミジノプロパン)二塩酸塩、2,2’−アゾビス
(N,N−ジメチレンイソブチルアミジン)二塩酸塩、
などのアゾ系開始剤、過酸化水素及び、過酸化ベンゾイ
ル、t−ブチルヒドロパーオキシド、クメンヒドロパー
オキシド、メチルエチルケトンパーオキシド、過安息香
酸などの有機過酸化物、過硫酸ナトリウム、過硫酸カリ
ウム、過硫酸アンモニウムなどの過硫酸塩、過酸化水素
−Fe3+などのレドックス開始剤、など既存のラジカル
開始剤を用いてもよいし、光増感剤の存在/又は非存在
下での光照射や、放射線照射により重合を開始させても
よい。
The polymer constituting the component (a) of the present invention may be obtained by any polymerization method, but a radical polymerization method is particularly preferred, and the polymerization can be carried out in a bulk, solution or emulsion system. The radical polymerization may be initiated by heating, but 2,2′-azobis (2-
Amidinopropane) dihydrochloride, 2,2′-azobis (N, N-dimethyleneisobutylamidine) dihydrochloride,
Azo initiators such as hydrogen peroxide and benzoyl peroxide, t-butyl hydroperoxide, cumene hydroperoxide, methyl ethyl ketone peroxide, organic peroxides such as perbenzoic acid, sodium persulfate, potassium persulfate, An existing radical initiator such as a persulfate such as ammonium persulfate, a redox initiator such as hydrogen peroxide-Fe 3+ may be used, or light irradiation in the presence / absence of a photosensitizer or Alternatively, the polymerization may be started by irradiation with radiation.

【0022】本発明の(a)成分は、モノマー単位Aの
単一重合体並びにモノマー単位A及びモノマー単位Bの
コポリマーから選ばれる重合体の複数種の混合物であっ
てもよい。
The component (a) of the present invention may be a homopolymer of the monomer unit A or a mixture of a plurality of polymers selected from a copolymer of the monomer units A and B.

【0023】本発明の(a)成分における、モノマー単
位Aの割合は10〜100モル%であるが、より好まし
くは20〜100モル%である。
The proportion of the monomer unit A in the component (a) of the present invention is from 10 to 100 mol%, preferably from 20 to 100 mol%.

【0024】本発明の(a)成分は本発明の硬質表面用
殺菌防汚剤の殺菌性、防汚性を著しく阻害しない限りに
おいて、重合体Aを含有しない他の水溶性重合体を含有
していてもよい。
The component (a) of the present invention contains another water-soluble polymer which does not contain the polymer A, as long as the bactericidal and antifouling properties of the bactericidal and antifouling agent for hard surfaces of the present invention are not significantly impaired. May be.

【0025】本発明の(a)成分は重量平均分子量が
1,000〜6,000,000、好ましくは10,0
00〜6,000,000、特に好ましくは100,0
00〜6,000,000であり、この重量平均分子量
はアセトニトリルと水の混合溶媒(リン酸緩衝液)を展
開溶媒とし、ゲルパーミエーションクロマトグラフィー
でポリエチレングリコールを標準物質として求めたもの
である。
The component (a) of the present invention has a weight average molecular weight of 1,000 to 6,000,000, preferably 10,000.
00 to 6,000,000, particularly preferably 100,0
The weight average molecular weight is determined by gel permeation chromatography using polyethylene glycol as a standard substance using a mixed solvent of acetonitrile and water (phosphate buffer) as a developing solvent.

【0026】(a)成分は本発明の殺菌防汚剤中に好ま
しくは0.01〜30重量%、より好ましくは0.01
〜20重量%、最も好ましくは0.01〜10重量%含
有される。
The component (a) is preferably contained in the bactericidal antifouling agent of the present invention in an amount of 0.01 to 30% by weight, more preferably 0.01 to 30% by weight.
-20% by weight, most preferably 0.01-10% by weight.

【0027】本発明の(b)成分は、分子量が1000
未満、好ましくは500以下の少なくとも1つの4級ア
ンモニウム基を有する殺菌性化合物である。本発明でい
う殺菌性とは、下記方法により測定されるコロニー数が
10以下であることをいう。
The component (b) of the present invention has a molecular weight of 1,000.
Fungicidal compounds having at least one quaternary ammonium group of less than 500, preferably less than 500. The term "bactericidal" as used in the present invention means that the number of colonies measured by the following method is 10 or less.

【0028】<殺菌性測定方法>供試菌として大腸菌
(Escherichia coli:IFO397
2)と黄色ブドウ球菌(Staphylococcus
aureus IFO12732)を用いる。試験化合
物〔(b)成分〕の1重量%水溶液を調製し、該水溶液
2ml中に108〜109個の細菌浮遊液50μlを加え
よく混合した後、5分間放置する。放置後、この混合液
を0.1ml採取して0.9mlのLP希釈液中に加え
て十分混合し、前記化合物の菌への影響を低下させ、次
いでこの混合液をSCDLP寒天培地上に塗布し、大腸
菌は37℃で24時間、黄色ブドウ球菌は37℃で48
時間培養する。培養後の生育したコロニー数を数える。
なお殺菌試験は同じ化合物についてそれぞれ同時に5回
ずつ行う(5回×3)。この実験結果において、大腸菌
及び黄色ブドウ球菌の両方のコロニー数が10以下とな
るものを殺菌性ありとする。なお、前記規定以外の実験
条件の詳細は、防菌防黴ハンドブック(日本防菌防黴学
会編、技報堂出版)のp686に記載されている浮遊試
験法(定量的検査法)に従う。
<Method of measuring bactericidal property> Escherichia coli (IFO397) was used as a test bacterium.
2) and Staphylococcus
aureus IFO12732). A 1% by weight aqueous solution of the test compound [component (b)] is prepared, and 50 μl of 10 8 to 10 9 bacterial suspensions are added to 2 ml of the aqueous solution, mixed well, and allowed to stand for 5 minutes. After standing, 0.1 ml of this mixture is collected and added to 0.9 ml of LP diluent and mixed well to reduce the effect of the compound on the bacterium. Then, this mixture is applied on an SCDLP agar medium. E. coli for 24 hours at 37 ° C, Staphylococcus aureus for 48 hours at 37 ° C.
Incubate for hours. Count the number of grown colonies after culturing.
The bactericidal test is carried out simultaneously 5 times for the same compound (5 times 3). In this experimental result, those in which the number of colonies of both Escherichia coli and Staphylococcus aureus are 10 or less are regarded as bactericidal. The details of the experimental conditions other than the above-mentioned rules are based on the floating test method (quantitative test method) described in p.686 of the Bacterial and Fungicide Handbook (edited by the Japan Society of Bacterial and Fungicide, published by Gihodo).

【0029】(b)成分となる分子量1000未満の殺
菌性化合物としては、下記一般式(1)〜(3)で示さ
れる化合物が好ましく、それらのうち特に水溶性のもの
が好ましい。ここで水溶性とは20℃の水1Lに溶解す
る量が1g以上であることを指す。
As the fungicidal compound having a molecular weight of less than 1,000, which is the component (b), compounds represented by the following general formulas (1) to (3) are preferable, and among them, water-soluble compounds are particularly preferable. Here, the term "water-soluble" means that the amount dissolved in 1 L of water at 20 ° C is 1 g or more.

【0030】[0030]

【化5】 Embedded image

【0031】〔式中、R1及びR6は、それぞれ独立して
炭素数6〜18、好ましくは8〜16のアルキル基又は
アルケニル基、好ましくはアルキル基であり、R3及び
4は、それぞれ独立して炭素数1〜3のアルキル基又
はヒドロキシアルキル基である。Xは芳香環又は−CO
O−、−CONH−、−OCO−、−NHCO−から選
ばれるエステル基あるいはアミド基であり、R2は、X
がエステル基又はアミド基である場合には水酸基で置換
されていてもよい炭素数1〜6のアルキレン基であり、
Xが芳香環の場合には、水酸基で置換されていてもよい
炭素数1〜6のアルキレン基又は−(O−R11)k−であ
る。ここでR11はエチレン基又はプロピレン基、好まし
くはエチレン基であり、kは平均1〜10、好ましくは
平均1〜5の数である。R5は炭素数1〜3のアルキレ
ン基である。R7〜R10はこれらの内1つ以上、好まし
くは1つ又は2つが炭素数8〜18、好ましくは8〜1
4、より好ましくは8〜12のアルキル基であり、残り
が炭素数1〜3のアルキル基又はヒドロキシアルキル基
である。また、mは0又は1の数である。さらにY
-は、陰イオンであり、特にハロゲンイオン、硫酸イオ
ン、炭素数1〜3のアルキル硫酸イオン、炭素数1〜3
のアルキル基で置換されていてもよい芳香族スルホン酸
イオンが好ましい。〕。
Wherein R 1 and R 6 are each independently an alkyl or alkenyl group having 6 to 18 carbon atoms, preferably 8 to 16 carbon atoms, preferably an alkyl group, and R 3 and R 4 are Each is independently an alkyl group having 1 to 3 carbon atoms or a hydroxyalkyl group. X is an aromatic ring or -CO
O -, - CONH -, - OCO -, - is an ester group or amide group selected from NHCO-, R 2 is, X
Is an ester group or an amide group, is an alkylene group having 1 to 6 carbon atoms which may be substituted with a hydroxyl group,
When X is an aromatic ring, it is an alkylene group having 1 to 6 carbon atoms which may be substituted with a hydroxyl group, or-(OR 11 ) k- . Here, R 11 is an ethylene group or a propylene group, preferably an ethylene group, and k is a number of 1 to 10 on average, preferably 1 to 5 on average. R 5 is an alkylene group having 1 to 3 carbon atoms. R 7 to R 10 is one or more of these, preferably one or two C8 to C18, preferably 8-1
4, more preferably an alkyl group of 8 to 12, and the rest being an alkyl group having 1 to 3 carbon atoms or a hydroxyalkyl group. M is a number of 0 or 1. Further Y
- is an anion, especially a halide ion, sulfate ion, alkyl sulfate ion having 1 to 3 carbon atoms, 1 to 3 carbon atoms
Aromatic sulfonate ions which may be substituted with an alkyl group are preferred. ].

【0032】より好ましい(b)成分は上記一般式
(1)又は(3)の化合物であり、最も好ましくは下記
の一般式の化合物である。
More preferred component (b) is a compound of the above formula (1) or (3), most preferably a compound of the following formula.

【0033】[0033]

【化6】 Embedded image

【0034】(b)成分は本発明の殺菌防汚剤中に好ま
しくは0.001〜30重量%、より好ましくは0.0
01〜20重量%、最も好ましくは0.005〜5重量
%含有される。
Component (b) is preferably present in the fungicidal and antifouling agent of the present invention in an amount of 0.001 to 30% by weight, more preferably 0.01 to 30% by weight.
The content is from 0.01 to 20% by weight, most preferably from 0.005 to 5% by weight.

【0035】本発明において、充分な防汚性を保った上
で、殺菌効果を得るために(a)成分/(b)成分は重
量比で20/1〜1/50が好ましく、10/1〜1/
20がより好ましく、5/1〜1/10が最も好まし
い。
In the present invention, the weight ratio of component (a) / component (b) is preferably from 20/1 to 1/50 in order to obtain a bactericidal effect while maintaining sufficient antifouling properties. ~ 1 /
20 is more preferable, and 5/1 to 1/10 is most preferable.

【0036】本発明の硬質表面用殺菌防汚剤は、良好な
殺菌性及び防汚性を有するものであるが、更に(c)と
して(b)成分以外の界面活性剤〔以下、(c)成分と
いう〕を含有することで、洗浄性が付与され、硬質表面
用殺菌防汚洗浄剤として使用することができる。界面活
性剤としては、非イオン界面活性剤、両性界面活性剤、
陰イオン界面活性剤から選ばれる1種以上の界面活性剤
を添加することが好ましい。
The bactericidal and antifouling agent for hard surfaces of the present invention has good bactericidal and antifouling properties, and further comprises (c) a surfactant other than the component (b) [hereinafter referred to as (c) Component)], thereby imparting detergency and being able to be used as a hard surface sterilizing and antifouling detergent. As surfactants, nonionic surfactants, amphoteric surfactants,
It is preferable to add one or more surfactants selected from anionic surfactants.

【0037】非イオン界面活性剤としては、下記一般式
(c1)〜一般式(c3)の化合物が挙げられる。 Rc1−O(EO)nH (c1) 〔式中、Rc1は平均炭素数10〜20、好ましくは10
〜18の一級の直鎖アルキル基、分岐鎖アルキル基又は
二級のアルキル基である。EOはエチレンオキサイドで
あり、nは平均付加モル数として5〜20である。〕 Rc2−O(EO)p/(PO)qH (c2) 〔式中、Rc2は平均炭素数10〜20、好ましくは10
〜18の一級のアルキル基である。EOはエチレンオキ
サイド、POはプロピレンオキサイドを示す。k及びl
は平均付加モル数であり、pは5〜15、qは1〜5で
ある。EOとPOはランダム付加又はEOを付加した
後、POを付加してもよく、またその逆のようなブロッ
ク付加体でもよい。また、ブロック付加体は3つ以上の
ブロックであってもよい。〕 Rc3−(ORc4)xy (c3) 〔式中、Rc3は直鎖又は分岐鎖の炭素数8〜18のアル
キル基もしくはアルケニル基又は炭素数8〜18のアル
キル基を有するアルキルフェニル基、Rc4は炭素数2〜
4のアルキレン基、Gは炭素数5又は6の還元糖に由来
する残基好ましくはグルコース残基であり、xは平均値
0〜6の数、yは平均値1〜10の数を示す。〕。
Examples of the nonionic surfactant include compounds represented by the following general formulas (c1) to (c3). R c1 —O (EO) n H (c1) wherein R c1 has an average carbon number of 10 to 20, preferably 10
~ 18 primary linear alkyl group, branched alkyl group or secondary alkyl group. EO is ethylene oxide, and n is 5 to 20 as an average number of added moles. R c2 —O (EO) p / (PO) q H (c2) wherein R c2 has an average carbon number of 10 to 20, preferably 10
~ 18 primary alkyl groups. EO indicates ethylene oxide, and PO indicates propylene oxide. k and l
Is the average number of moles added, p is 5 to 15, and q is 1 to 5. EO and PO may be added randomly, or PO may be added after EO is added, or vice versa. Further, the block additional body may be three or more blocks. R c3- (OR c4 ) x G y (c3) wherein R c3 is a linear or branched alkyl group or alkenyl group having 8 to 18 carbon atoms or an alkyl group having an alkyl group having 8 to 18 carbon atoms. Phenyl group, R c4 has 2 to 2 carbon atoms
The alkylene group of 4, G is a residue derived from a reducing sugar having 5 or 6 carbon atoms, preferably a glucose residue, x represents a number having an average value of 0 to 6, and y represents a number having an average value of 1 to 10. ].

【0038】両性界面活性剤としては下記一般式(c
4)で表されるアミンオキシド及び一般式(c5)で表
されるベタインを挙げることができる。
As the amphoteric surfactant, the following general formula (c)
The amine oxide represented by 4) and betaine represented by the general formula (c5) can be exemplified.

【0039】[0039]

【化7】 Embedded image

【0040】〔式中、Rc5は炭素数8〜18のアルキル
基又はアルケニル基であり、Rc7、R c8は、それぞれ独
立して、炭素数1〜3のアルキル基又はヒドロキシアル
キル基である。Rc6は炭素数1〜5のアルキレン基であ
る。Aは−COO−、−CONH−、−OCO−、−N
HCO−、−O−から選ばれる基であり、rは0又は1
の数である。〕
[Wherein, Rc5Is alkyl having 8 to 18 carbon atoms
Or an alkenyl group,c7, R c8Is German
Standing, an alkyl group having 1 to 3 carbon atoms or hydroxyal
It is a kill group. Rc6Is an alkylene group having 1 to 5 carbon atoms
You. A represents -COO-, -CONH-, -OCO-, -N
HCO- or -O-, wherein r is 0 or 1
Is the number of ]

【0041】[0041]

【化8】 Embedded image

【0042】〔式中、Rc5、Rc6、Rc7、Rc8、A及び
rは前記一般式(c4)記載のものと同じである。Rc9
は水酸基で置換されていてもよい炭素数1〜5のアルキ
レン基であり、Tは−OSO3 -、−COO-、−SO3 -
から選ばれる陰イオン基である。rは0又は1の数であ
る。〕。
[Wherein R c5 , R c6 , R c7 , R c8 , A and r are the same as those described in the general formula (c4). R c9
Is an alkylene group of 1 to 5 carbon atoms which may be substituted with a hydroxyl group, T is -OSO 3 -, -COO -, -SO 3 -
An anionic group selected from r is a number of 0 or 1. ].

【0043】陰イオン界面活性剤としてはアルキル基の
炭素数8〜18のアルキルベンゼンスルホン酸塩、アル
カンスルホン酸塩、αオレフィンスルホン酸塩、アルキ
ル硫酸エステル塩、ポリオキシエチレンアルキルエーテ
ル硫酸塩、ポリオキシエチレンアルキルエーテル酢酸塩
等を挙げることができる。
Examples of the anionic surfactant include an alkylbenzene sulfonate having 8 to 18 carbon atoms, an alkane sulfonate, an α-olefin sulfonate, an alkyl sulfate, a polyoxyethylene alkyl ether sulfate, and a polyoxyalkylene sulfonate. Examples thereof include ethylene alkyl ether acetate.

【0044】本発明では特に前記一般式(c3)及び
(c4)から選ばれる界面活性剤の一種以上を配合する
ことが、防汚効果を損なうことなく優れた洗浄性を得る
上で好ましい。(c)成分の界面活性剤の配合量は、殺
菌及び防汚効果を損なうことなく十分な洗浄力を得るた
めに好ましくは0.01重量%以上、20重量%未満、
より好ましくは0.1重量%以上であり、特に好ましく
は0.1〜15重量%である。
In the present invention, it is particularly preferable to incorporate at least one of the surfactants selected from the general formulas (c3) and (c4) in order to obtain excellent detergency without impairing the antifouling effect. The amount of the surfactant (c) is preferably 0.01% by weight or more and less than 20% by weight in order to obtain a sufficient detergency without impairing the sterilizing and antifouling effects.
It is more preferably at least 0.1% by weight, particularly preferably from 0.1 to 15% by weight.

【0045】但し、陰イオン界面活性剤とベタイン型両
性界面活性剤(4級アンモニウム基と、スルホン酸基ま
たはカルボキシ基とを有する両性界面活性剤)は、殺菌
性及び防汚性を低下させるため、影響のない量で配合さ
れるべきであり、具体的には本発明の硬質表面用殺菌防
汚剤中5.0重量%を超えない量、より好ましくは3.
0重量%以下、最も好ましくは1.0重量%以下の量で
配合される。
However, anionic surfactants and betaine-type amphoteric surfactants (amphoteric surfactants having a quaternary ammonium group and a sulfonic acid group or a carboxy group) reduce bactericidal and antifouling properties. , In an amount that does not affect, specifically, an amount that does not exceed 5.0% by weight, more preferably 3.
0% by weight or less, most preferably 1.0% by weight or less.

【0046】本発明では、(d)成分として、有機汚れ
に対する洗浄力向上の目的で水溶性溶剤を配合すること
が好ましく、[1]炭素数1〜5の1価アルコール、
[2]炭素数4〜12の多価アルコール、[3]下記の
一般式(d1)で表される化合物、[4]下記の一般式
(d2)で表される化合物及び[5]下記の一般式(d
3)で表される化合物から選ばれる一種以上が好まし
い。
In the present invention, it is preferable to add a water-soluble solvent as component (d) for the purpose of improving the detergency against organic stains, [1] a monohydric alcohol having 1 to 5 carbon atoms,
[2] a polyhydric alcohol having 4 to 12 carbon atoms, [3] a compound represented by the following general formula (d1), [4] a compound represented by the following general formula (d2), and [5] the following The general formula (d
One or more compounds selected from the compounds represented by 3) are preferable.

【0047】[0047]

【化9】 Embedded image

【0048】〔式中、Rd1及びRd2は、それぞれ独立し
て、水素原子、炭素数1〜8のアルキル基、フェニル基
又はベンジル基を示すが、Rd11及びRd2の双方が水素
原子となる場合を除く。s及びtは、それぞれ独立し
て、0〜10の数を示すが、s及びtの双方が0である
場合を除く。Rd3及びRd4は炭素数1〜3のアルキル基
を示す。Rd5は炭素数1〜3のアルキル基を示す。〕。
[0048] wherein, R d1 and R d2 each independently represent a hydrogen atom, an alkyl group having 1 to 8 carbon atoms, but a phenyl group or a benzyl group, both R d1 1 and R d2 is a hydrogen Except when it becomes an atom. s and t each independently represent a number from 0 to 10, except when both s and t are 0. R d3 and R d4 each represent an alkyl group having 1 to 3 carbon atoms. R d5 represents an alkyl group having 1 to 3 carbon atoms. ].

【0049】[1]の炭素数2〜5の1価アルコールと
しては、一般的にエタノール、プロピルアルコール、イ
ソプロピルアルコールが挙げられる。これらの低級アル
コールを配合することにより低温における系の安定性を
更に向上させることができる。
The monohydric alcohol having 2 to 5 carbon atoms [1] generally includes ethanol, propyl alcohol and isopropyl alcohol. By incorporating these lower alcohols, the stability of the system at low temperatures can be further improved.

【0050】[2]の炭素数4〜12の多価アルコール
としては、イソプレングリコール、2,2,4−トリメ
チル−1,3−ペンタンジオール、1,8−オクタンジ
オール、1,9−ノナンジオール、エチレングリコー
ル、プロピレングリコール、ジエチレングリコール、ジ
プロピレングリコール、グリセリンの他、アルキル基の
炭素数が3〜8のモノアルキルグリセリルエーテル等が
挙げられる。
The polyhydric alcohol having 4 to 12 carbon atoms [2] includes isoprene glycol, 2,2,4-trimethyl-1,3-pentanediol, 1,8-octanediol, and 1,9-nonanediol , Ethylene glycol, propylene glycol, diethylene glycol, dipropylene glycol, glycerin, and monoalkyl glyceryl ether having an alkyl group having 3 to 8 carbon atoms.

【0051】[3]の化合物は、一般式(d1)におい
て、Rd1、Rd2がアルキル基である場合の炭素数は1〜
4が特に好ましい。また、一般式(d1)中、エチレン
オキサイド(以下、EOという)及びプロピレンオキサ
イド(以下、POという)の平均付加モル数のs及びt
は、それぞれ0〜10の数であるが、EOとPOの付加
順序は特に限定されず、ランダム付加したものであって
もよい。[3]の化合物の具体例としては、エチレング
リコールモノブチルエーテル、ジプロピレングリコール
ジメチルエーテル、ジエチレングリコールモノエチルエ
ーテル、ジエチレングリコールモノブチルエーテル、プ
ロピレングリコールモノメチルエーテル、プロピレング
リコールモノプロピルエーテル、プロピレングリコール
モノブチルエーテル、プロピレングリコールモノエチル
エーテル、プロピレングリコールジメチルエーテル、ポ
リオキシエチレン(平均付加モル数=2〜3)ポリオキ
シプロピレン(平均付加モル数=2〜3)グリコールジ
メチルエーテル、ポリオキシエチレン(平均付加モル数
=1〜4)グリコールフェニルエーテル、フェニルカル
ビトール、フェニルセロソルブ、ベンジルカルビトール
等が挙げられる。このうち、洗浄力及び使用感の点か
ら、プロピレングリコールモノメチルエーテル、ジエチ
レングリコールモノブチルエーテル、ポリオキシエチレ
ン(平均付加モル数=1〜4)グリコールフェニルエー
テルが好ましい。
The compound of [3] has a carbon number of 1 to 1 when R d1 and R d2 are alkyl groups in the general formula (d1).
4 is particularly preferred. Further, in the general formula (d1), s and t are average addition mole numbers of ethylene oxide (hereinafter, referred to as EO) and propylene oxide (hereinafter, referred to as PO).
Is a number from 0 to 10, respectively, but the order of addition of EO and PO is not particularly limited, and may be random addition. Specific examples of the compound [3] include ethylene glycol monobutyl ether, dipropylene glycol dimethyl ether, diethylene glycol monoethyl ether, diethylene glycol monobutyl ether, propylene glycol monomethyl ether, propylene glycol monopropyl ether, propylene glycol monobutyl ether, and propylene glycol monoethyl. Ether, propylene glycol dimethyl ether, polyoxyethylene (average addition mole number = 2-3) polyoxypropylene (average addition mole number = 2-3) glycol dimethyl ether, polyoxyethylene (average addition mole number = 1-4) glycol phenyl Ether, phenyl carbitol, phenyl cellosolve, benzyl carbitol and the like. Among these, propylene glycol monomethyl ether, diethylene glycol monobutyl ether, and polyoxyethylene (average number of moles = 1 to 4) glycol phenyl ether are preferred from the viewpoints of detergency and usability.

【0052】また、[4]の化合物としては、1,3−
ジメチル−2−イミダゾリジノン、1,3−ジエチル−
2−イミダゾリジノンが好適なものとして例示され、
[5]の化合物としては3−メトキシ−3−メチルブタ
ノール、3−エトキシ−3−メチルブタノール等が好ま
しい。
The compound of [4] includes 1,3-
Dimethyl-2-imidazolidinone, 1,3-diethyl-
2-imidazolidinone is exemplified as being preferred,
As the compound of [5], 3-methoxy-3-methylbutanol, 3-ethoxy-3-methylbutanol and the like are preferable.

【0053】これらのなかでも基材に対する損傷性の点
から[1]、[2]及び[3]の化合物から選ばれる水
溶性溶剤が好ましく、特にエタノール、イソプロピルア
ルコール、エチレングリコール、プロピレングリコー
ル、ジエチレングリコール、ジプロピレングリコール、
グリセリン、イソプレングリコール、プロピレングリコ
ールモノメチルエーテル、プロピレングリコールモノエ
チルエーテル、プロピレングリコールモノプロピルエー
テル、プロピレングリコールモノブチルエーテル及びア
ルキル基の炭素数が3〜8のモノアルキルグリセリルエ
ーテルから選ばれる水溶性溶剤が好ましい。
Among these, water-soluble solvents selected from the compounds [1], [2] and [3] are preferable from the viewpoint of damage to the substrate, and particularly ethanol, isopropyl alcohol, ethylene glycol, propylene glycol and diethylene glycol. , Dipropylene glycol,
A water-soluble solvent selected from glycerin, isoprene glycol, propylene glycol monomethyl ether, propylene glycol monoethyl ether, propylene glycol monopropyl ether, propylene glycol monobutyl ether and monoalkyl glyceryl ether having an alkyl group having 3 to 8 carbon atoms is preferable.

【0054】(d)成分の水溶性溶剤は、本発明の殺菌
性防汚剤中に好ましくは0.1〜20重量%、より好ま
しくは0.5〜10重量%、最も好ましくは1〜10重
量%含有される。
The water-soluble solvent of the component (d) is preferably 0.1 to 20% by weight, more preferably 0.5 to 10% by weight, most preferably 1 to 10% by weight in the germicidal antifouling agent of the present invention. % By weight.

【0055】本発明では無機汚れを溶解し、洗浄力及び
殺菌効果を向上させる目的で、さらに(e)成分とし
て、キレート剤を配合することが好ましい。キレート剤
としては(1)トリポリリン酸、ピロリン酸、オルソリ
ン酸、ヘキサメタリン酸及びこれらのアルカリ金属塩、
(2)エチレンジアミン四酢酸、ヒドロキシイミノ二酢
酸、ジヒドロキシエチルグリシン、ニトリロ三酢酸、ヒ
ドロキシエチレンジアミン三酢酸、ジエチレントリアミ
ン五酢酸、トリエチレンテトラミン六酢酸及びこれらの
アルカリ金属塩もしくはアルカリ土類金属塩、(3)ア
ミノトリメチレンホスホン酸、1−ヒドロキシエチリデ
ン−1,1−ジホスホン酸、エチレンジアミンテトラメ
チレンホスホン酸、ジエチレントリアミンペンタメチレ
ンホスホン酸、アミノトリメチレンホスホン酸のN−オ
キサイド及びこれらのアルカリ金属塩もしくはアルカリ
土類金属塩、(4)アクリル酸及びメタクリル酸から選
ばれるモノマーの単一重合体又は共重合体、アクリル酸
−マレイン酸共重合体、ポリα−ヒドロキアクリル酸及
びそのアルカリ金属塩、(5)クエン酸、コハク酸、リ
ンゴ酸、フマル酸、酒石酸、マロン酸、マレイン酸から
選ばれる多価カルボン酸及びそれらのアルカリ金属塩か
ら選ばれる1種以上、(6)アルキルグリシン−N,N
−ジ酢酸、アスパラギン酸−N,N−ジ酢酸、セリン−
N,N−ジ酢酸、グルタミン酸二酢酸、エチレンジアミ
ンジコハク酸又はこれらの塩が好ましく、特に(2)、
(3)、(5)の化合物が好ましい。
In the present invention, for the purpose of dissolving the inorganic soil and improving the detergency and the sterilizing effect, it is preferable to further add a chelating agent as the component (e). Examples of the chelating agent include (1) tripolyphosphoric acid, pyrophosphoric acid, orthophosphoric acid, hexametaphosphoric acid and alkali metal salts thereof,
(2) ethylenediaminetetraacetic acid, hydroxyiminodiacetic acid, dihydroxyethylglycine, nitrilotriacetic acid, hydroxyethylenediaminetriacetic acid, diethylenetriaminepentaacetic acid, triethylenetetraminehexaacetic acid and alkali metal salts or alkaline earth metal salts thereof, (3) N-oxides of aminotrimethylenephosphonic acid, 1-hydroxyethylidene-1,1-diphosphonic acid, ethylenediaminetetramethylenephosphonic acid, diethylenetriaminepentamethylenephosphonic acid, aminotrimethylenephosphonic acid and alkali metal salts or alkaline earth metals thereof Salt, (4) a homopolymer or copolymer of a monomer selected from acrylic acid and methacrylic acid, an acrylic acid-maleic acid copolymer, poly α-hydroxyacrylic acid and its alkali gold Salts, (5) one or more polycarboxylic acids selected from citric acid, succinic acid, malic acid, fumaric acid, tartaric acid, malonic acid, maleic acid and alkali metal salts thereof, and (6) alkylglycine- N, N
-Diacetic acid, aspartic acid-N, N-diacetic acid, serine-
N, N-diacetate, glutamic acid diacetate, ethylenediamine disuccinic acid or salts thereof are preferred, and particularly (2)
The compounds (3) and (5) are preferred.

【0056】(e)成分のキレート剤は、本発明の殺菌
性防汚剤中に好ましくは0.1〜20重量%、より好ま
しくは0.1〜10重量%、最も好ましくは0.5〜1
0重量%含有される。
The chelating agent of the component (e) is preferably 0.1 to 20% by weight, more preferably 0.1 to 10% by weight, most preferably 0.5 to 10% by weight in the germicidal antifouling agent of the present invention. 1
0% by weight is contained.

【0057】本発明は、pHを調整する場合にpH調整
剤を使用してもよい。pH調整剤としては塩酸や硫酸な
ど無機酸や、クエン酸、コハク酸、リンゴ酸、フマル
酸、酒石酸、マロン酸、マレイン酸などの有機酸などの
酸剤や、水酸化ナトリウムや水酸化カリウム、アンモニ
アやその誘導体、モノエタノールアミンやジエタノール
アミン、トリエタノールアミンなどのアミン塩など、炭
酸ナトリウム、炭酸カリウムなどのアルカリ剤を、単独
もしくは複合して用いても構わない。また、これらの酸
剤とアルカリ剤を組み合わせて緩衝剤系として用いても
構わない。
In the present invention, a pH adjuster may be used when adjusting the pH. Examples of the pH adjusting agent include inorganic acids such as hydrochloric acid and sulfuric acid, and acid agents such as citric acid, succinic acid, malic acid, fumaric acid, tartaric acid, malonic acid, maleic acid and other organic acids, sodium hydroxide and potassium hydroxide, Alkaline agents such as sodium carbonate and potassium carbonate such as ammonia and derivatives thereof, amine salts such as monoethanolamine, diethanolamine and triethanolamine may be used alone or in combination. Further, these acid agents and alkali agents may be used in combination as a buffer system.

【0058】本発明の硬表面用殺菌防汚剤は、上記のp
H調整剤により、20℃におけるpHが2〜12になる
ように調整することが好ましく、特にpH3〜11にな
るようにすることが防汚効果の点から好ましい。
The hard surface germicidal antifouling agent of the present invention comprises the above p
It is preferable to adjust the pH at 20 ° C. to 2 to 12 with an H adjuster, and it is particularly preferable to adjust the pH to 3 to 11 from the viewpoint of the antifouling effect.

【0059】本発明では使用時の付着性を持たせ使いや
すさ向上の目的で、水溶性高分子の1種以上を添加する
ことが出来る。水溶性高分子としては特に限定されるも
のではないが、特開平8−209194号公報6頁10
欄〜7頁11欄に記載の水溶性高分子から選ばれる1種
以上が好ましい。
In the present invention, one or more water-soluble polymers can be added for the purpose of imparting adhesion during use and improving ease of use. The water-soluble polymer is not particularly limited, but is disclosed in JP-A-8-209194, p.
Column 1 to page 7 column 11 are preferably one or more selected from the water-soluble polymers.

【0060】本発明の硬表面用殺菌防汚剤には、上記成
分の他に、本発明の効果を損なわない範囲で通常の洗浄
剤に配合されている添加剤、例えば香料、抗菌剤、粘度
調整剤、顔料、染料、懸濁剤などを添加することができ
る。また、使用時の起泡性を高める目的で、トルエンス
ルホン酸、キシレンスルホン酸、クメンスルホン酸、ア
ルケニルコハク酸及びこれらのアルカリ金属塩などの起
泡助剤から選ばれる1種以上を添加することが出来る。
The hard surface germicidal antifouling agent of the present invention includes, in addition to the above-mentioned components, additives incorporated in ordinary detergents as long as the effects of the present invention are not impaired, such as fragrances, antibacterial agents, and viscosities. Adjusters, pigments, dyes, suspending agents and the like can be added. Further, for the purpose of enhancing the foaming property at the time of use, at least one selected from foaming assistants such as toluenesulfonic acid, xylenesulfonic acid, cumenesulfonic acid, alkenylsuccinic acid and alkali metal salts thereof is added. Can be done.

【0061】本発明を使用する際には、(a)成分の重
合体と(b)成分の殺菌化合物とを、溶媒中に一剤とし
て溶解または分散させても、任意成分との組み合わせに
よる、任意の剤数にしても構わない。また、任意成分を
組み合わせることにより、水などの溶媒に対して、直ち
に溶解する、あるいは徐放性を付与した、一剤以上の粉
末や錠剤の形状で用いても構わない。さらに、(a)成
分と(b)成分、あるいは任意成分のいずれかが液状で
他方が粉末などの固体状で用いることもできる。
When the present invention is used, the polymer of the component (a) and the germicidal compound of the component (b) may be dissolved or dispersed as a single agent in a solvent, or may be used in combination with an optional component. Any number of agents may be used. In addition, by combining optional components, it may be used in the form of one or more powders or tablets which are immediately dissolved in a solvent such as water or provided with sustained release. Further, any one of the component (a) and the component (b) or the optional component may be used in a liquid state, and the other may be used in a solid state such as a powder.

【0062】本発明の殺菌防汚剤の使用時の形態は、特
に問わないが、(a)成分、(b)成分及び任意成分を
含有し残部が水の液体組成物か、またはポリエチレング
リコール、脂肪酸等の凝固剤を用いて固体状もしくはゲ
ル状の組成物としてもよい。本発明の殺菌防汚剤を液体
組成物として被洗浄対象である硬質表面に直接塗布する
ような場合は、該組成物中の(a)成分の含有量は、好
ましくは0.01〜10重量%、より好ましくは0.0
1〜5重量%、最も好ましくは0.01〜3重量%であ
り、(b)成分の含有量は、好ましくは0.001〜5
重量%、より好ましくは0.001〜3重量%、最も好
ましくは0.005〜3重量%であり、(c)成分の含
有量は、好ましくは0.01〜10重量%、より好まし
くは0.1〜8重量%、最も好ましくは0.1〜5重量
%であり、(d)成分の含有量は、好ましくは0.1〜
5重量%、より好ましくは0.5〜5重量%、最も好ま
しくは1〜3重量%であり、(e)成分の含有量は、好
ましくは0.1〜15重量%、より好ましくは0.1〜
10重量%、最も好ましくは0.5〜10重量%が好ま
しく、高い濃度の溶液を使用の直前に水道水などで希釈
することによって調製してもよい。また、これら液体組
成物には、壁面への付着性を上げるためにキサンタンガ
ム等の増粘剤を配合してもよい。なお、直接塗布する場
合は前記殺菌防汚剤ないしその洗浄剤を、被洗浄体へ直
接噴霧、散布又は塗布することができるトリガースプレ
ーヤーを備えた容器、またはスクイズ容器等の吐出機構
を有する容器に充填した物品とすることが最も好まし
い。
The mode of use of the germicidal antifouling agent of the present invention is not particularly limited, but is a liquid composition containing component (a), component (b) and optional components, with the balance being water or polyethylene glycol, A solid or gel composition may be prepared using a coagulant such as a fatty acid. When the germicidal antifouling agent of the present invention is directly applied as a liquid composition to a hard surface to be cleaned, the content of the component (a) in the composition is preferably 0.01 to 10% by weight. %, More preferably 0.0
The content of the component (b) is preferably 0.001 to 5% by weight, most preferably 0.01 to 3% by weight.
%, More preferably 0.001 to 3% by weight, most preferably 0.005 to 3% by weight, and the content of the component (c) is preferably 0.01 to 10% by weight, more preferably 0 to 10% by weight. 0.1 to 8% by weight, most preferably 0.1 to 5% by weight, and the content of the component (d) is preferably 0.1 to 5% by weight.
The content is 5% by weight, more preferably 0.5 to 5% by weight, most preferably 1 to 3% by weight, and the content of the component (e) is preferably 0.1 to 15% by weight, more preferably 0.1 to 15% by weight. 1 to
It is preferably 10% by weight, most preferably 0.5 to 10% by weight, and may be prepared by diluting a high concentration solution with tap water or the like immediately before use. Further, a thickener such as xanthan gum may be added to these liquid compositions in order to increase the adhesion to the wall surface. In the case of direct application, a container provided with a trigger sprayer capable of directly spraying, spraying or applying the sterilizing / fouling agent or the cleaning agent onto a body to be cleaned, or a container having a discharge mechanism such as a squeeze container It is most preferred that the article is filled with a.

【0063】また、固体状またはゲル状の場合は、トイ
レ水洗用タンクに用いるオートクリーナーとして有用で
ある。
In the case of a solid or gel, it is useful as an auto cleaner used for a toilet flush tank.

【0064】[0064]

【実施例】表1に示す組成の殺菌防汚剤を調製し、その
防汚性及び殺菌性について下記の方法で評価した。結果
を表1に示す。
EXAMPLES A bactericidal antifouling agent having the composition shown in Table 1 was prepared, and its antifouling property and bactericidal property were evaluated by the following methods. Table 1 shows the results.

【0065】<防汚性の評価> (1)易洗浄性 殺菌防汚剤1mLを、面積10cm2の陶器タイル表面
に塗布し、5分間放置した後、水200mLを45°の
角度で流速25mL/秒の割合で流し、乾燥させること
を5回繰り返して行った後、陶器タイル表面にスポット
状にオレイン酸を0.5g滴下する。オレイン酸を滴下
した陶器タイルを、オレイン酸が流れないよう、水槽の
底に静置し、陶器タイルに直接水がかからないよう、静
かに水槽中に水を満たしていく。その際のオレイン酸が
陶器タイル表面から除去される面積の割合を判定し、次
の5段階で評価した。なお、汚れ落ちの%はモデル汚染
板5枚の平均値を採用した。 5:汚れ落ちが80%以上である 4:汚れ落ちが60%以上80%未満である 3:汚れ落ちが40%以上60%未満である 2:汚れ落ちが20%以上40%未満である 1:汚れ落ちが20%未満である。
<Evaluation of antifouling property> (1) Easy cleaning property 1 mL of a sterilizing antifouling agent was applied to the surface of a ceramic tile having an area of 10 cm 2 , allowed to stand for 5 minutes, and then 200 mL of water was flowed at a 45 ° angle at a flow rate of 25 mL. After repeating the flow and drying at a rate of 5 times / second, 0.5 g of oleic acid is dropped on the surface of the ceramic tile in the form of spots. The ceramic tile with the oleic acid dropped on it is kept at the bottom of the water tank so that oleic acid does not flow, and the water is gently filled with water so that the ceramic tile is not directly exposed to water. At that time, the ratio of the area where oleic acid was removed from the surface of the ceramic tile was determined, and evaluated in the following five steps. In addition, the average value of five model-contaminated plates was adopted as the percentage of stain removal. 5: The stain removal is 80% or more 4: The stain removal is 60% or more and less than 80% 3: The stain removal is 40% or more and less than 60% 2: The stain removal is 20% or more and less than 40% 1. : Stain removal is less than 20%.

【0066】(2)汚れ付着防止性 市販の便器(C730B、東陶機器(株)製)を用い、
汚れの付きにくさの評価を行った。即ち組成物で便器を
洗浄し、1週間放置した際の汚れの付きにくさを、以下
の基準を基に肉眼で測定した。
(2) Antifouling property A commercially available toilet bowl (C730B, manufactured by TOTO Kiki Co., Ltd.) was used.
Evaluation of the difficulty of attaching dirt was performed. That is, the toilet was washed with the composition, and the degree of soiling when left for one week was visually measured based on the following criteria.

【0067】 (評価基準) ◎:汚れが付いていない。 ○:汚れが僅かに付いている。 △:汚れが少し付いている。 ×:汚れがかなり付いている。(Evaluation Criteria) A: There is no stain. :: Slightly adhered. Δ: Slightly adhered. ×: There is considerable dirt.

【0068】<殺菌性評価>供試菌として大腸菌(Es
cherichia coli:IFO3972)と黄
色ブドウ球菌(Staphylococcus aur
eus IFO12732)を用いた。
<Evaluation of bactericidal property> Escherichia coli (Es
cherichia coli (IFO3972) and Staphylococcus aur
eus IFO12732) was used.

【0069】殺菌性試験は、表1に示す殺菌防汚剤2m
l中に108〜109個の細菌浮遊液50μlを加えよく
混合した後、放置時間を5分とした時の殺菌性を調べ
た。放置後、その混合液を0.1ml採取して0.9m
lのLP希釈液中に加えて十分混合し、洗浄液の菌への
影響を低下させ、次いでこの混合液をSCDLP寒天培
地上に塗布し、大腸菌は37℃で24時間、黄色ブドウ
球菌は37℃で48時間培養する。培養後の生育したコ
ロニー数を数える。なお殺菌試験は、同じ殺菌防汚剤に
ついて、各放置時間毎にそれぞれ5つの試験区により行
ない、以下の評点で殺菌性を評価した。
The bactericidal test was carried out using 2 m of the germicidal antifouling agent shown in Table 1.
After 50 μl of 10 8 to 10 9 bacterial suspensions were added and mixed well, the bactericidal activity when the standing time was set to 5 minutes was examined. After standing, 0.1 ml of the mixture was collected and 0.9 m
1 L of LP diluent and mixed well to reduce the effect of the washings on the bacteria, then apply this mixture on SCDLP agar medium for 24 hours at 37 ° C for E. coli and 37 ° C for Staphylococcus aureus. And culture for 48 hours. Count the number of grown colonies after culturing. In addition, the sterilization test performed the same sterilization antifouling agent by five test sections each for each leaving time, and evaluated the sterilization by the following scores.

【0070】なお、前記規定以外の実験条件の詳細は、
防菌防黴ハンドブック(日本防菌防黴学会編、技報堂出
版)のp686に記載されている浮遊試験法(定量的検
査法)に従う。 ○:放置時間が5分でのコロニー数が104以下にな
る。 ×:放置時間が5分でのコロニー数が104を超える
The details of the experimental conditions other than the above-mentioned rules were as follows.
The floating test method (quantitative test method) described in p.686 of the Bactericidal and Fungicide Handbook (edited by the Japan Society of Bacterial and Fungicide, published by Gihodo). :: The number of colonies after leaving for 5 minutes is 10 4 or less. ×: The number of colonies in a standing time of 5 minutes exceeds 10 4

【0071】[0071]

【表1】 [Table 1]

【0072】・重合体A:マーコート550[塩化ジア
リルジメチルアンモニウムとアクリルアミド(モル比3
0/70)共重合体(Calgon社製、重量平均分子
量500万、ゲルパーミエーションクロマトグラムによ
り測定、ポリエチレングリコールを標準として使用)] ・重合体B:マーコート100[塩化ジアリルジメチル
アンモニウムのホモポリマー(Calgon社製、重量
平均分子量40万、ゲルパーミエーションクロマトグラ
ムで測定、ポリエチレングリコールを標準として使
用)] ・殺菌性化合物A:サニゾールC[ココアルキルジメチ
ルベンジルアンモニウムクロリド(花王(株)製)] ・殺菌性化合物B:コータミンD10P[ジデシルジメ
チルアンモニウムクロリド(花王(株)製)] ・殺菌性化合物C:塩化ベンゼトニウム[和光試薬、下
記構造のカチオン化合物]
Polymer A: Mercoat 550 [diallyldimethylammonium chloride and acrylamide (molar ratio 3
0/70) Copolymer (manufactured by Calgon, weight average molecular weight 5,000,000, measured by gel permeation chromatogram, using polyethylene glycol as a standard)] Polymer B: Mercoat 100 [diallyldimethylammonium chloride homopolymer ( Calgon, weight average molecular weight: 400,000, measured by gel permeation chromatogram, using polyethylene glycol as a standard)] Bactericidal compound A: Sanisole C [cocoalkyldimethylbenzylammonium chloride (manufactured by Kao Corporation)] Fungicidal compound B: Cotamine D10P [didecyldimethylammonium chloride (manufactured by Kao Corporation)] Fungicidal compound C: Benzethonium chloride [Wako reagent, cationic compound having the following structure]

【0073】[0073]

【化10】 Embedded image

【0074】・AO:アンヒトール20N[ラウリルジ
メチルアミンオキシド(花王(株)製)] ・AG:アルキルグルコシド(直鎖アルキル基の炭素数
が12と14の混合物、糖平均縮合度1.2[縮合度1
と2の混合物]) ・ES:EO平均付加モル数が2.2モルのポリオキシ
エチレンラウリルエーテル硫酸 ・ベタイン:N−ラウロイルアミノプロピル−N,N−
ジメチル−N−カルボキシメチルアンモニウムベタイン ・EDTA−4Na:エチレンジアミン四酢酸四ナトリ
ウム塩 ・pH調整剤:塩酸及び/又は水酸化ナトリウム(何れ
も水溶液で用いる)
AO: Amphitol 20N [lauryl dimethylamine oxide (manufactured by Kao Corporation)] AG: Alkyl glucoside (a mixture of straight-chain alkyl groups having 12 to 14 carbon atoms, average sugar condensation degree 1.2 [condensation] Degree 1
And 2]) ES: polyoxyethylene lauryl ether sulfate having an average addition mole number of 2.2 mol betaine: N-lauroylaminopropyl-N, N-
Dimethyl-N-carboxymethylammonium betaine EDTA-4Na: tetrasodium ethylenediaminetetraacetate pH adjuster: hydrochloric acid and / or sodium hydroxide (all used in aqueous solution)

───────────────────────────────────────────────────── フロントページの続き (72)発明者 佃 一訓 和歌山県和歌山市湊1334 花王株式会社研 究所内 Fターム(参考) 4H003 AC05 AC08 AC15 AD04 AE05 AE06 AE08 BA12 DA05 DA17 EA03 EA21 EB08 EB16 EB28 EB30 EB32 ED02 ED28 FA06 FA28 FA34  ──────────────────────────────────────────────────続 き Continuing on the front page (72) Inventor Kazunori Tsukuda 1334 Minato, Wakayama City, Wakayama Pref. ED02 ED28 FA06 FA28 FA34

Claims (4)

【特許請求の範囲】[Claims] 【請求項1】 (a)重量平均分子量が1,000〜
6,000,000であって、4級アンモニウム基を有
するモノマー単位の比率が全モノマー単位に対して10
〜100モル%である重合体、及び(b)分子量が1,
000未満であって、4級アンモニウム基を有する殺菌
性化合物を含有する硬質表面用殺菌防汚剤。
(1) a weight average molecular weight of 1,000 to
6,000,000, and the ratio of monomer units having a quaternary ammonium group is 10
And (b) a molecular weight of 1,
A bactericidal antifouling agent for hard surfaces containing a bactericidal compound having a quaternary ammonium group, which is less than 000.
【請求項2】 (b)が下記一般式(1)〜(3)で表
される化合物から選ばれる一種以上の殺菌性化合物であ
る請求項1記載の硬質表面用殺菌防汚剤。 【化1】 〔式中、R1及びR6は、それぞれ独立して炭素数6〜1
8のアルキル基又はアルケニル基であり、R3及びR
4は、それぞれ独立して炭素数1〜3のアルキル基又は
ヒドロキシアルキル基である。Xは芳香環又は−COO
−、−CONH−、−OCO−、−NHCO−から選ば
れるエステル基あるいはアミド基であり、R2は、Xが
エステル基又はアミド基である場合には水酸基で置換さ
れていてもよい炭素数1〜6のアルキレン基であり、X
が芳香環の場合には、水酸基で置換されていてもよい炭
素数1〜6のアルキレン基又は−(O−R11)k−であ
る。ここでR11はエチレン基又はプロピレン基であり、
kは平均1〜10の数である。R5は炭素数1〜3のア
ルキレン基である。R7〜R10はこれらの内1つ以上が
炭素数8〜18のアルキル基であり、残りが炭素数1〜
3のアルキル基又はヒドロキシアルキル基である。ま
た、mは0又は1の数である。さらにY-は、陰イオン
である。〕
2. The germicidal and antifouling agent for hard surfaces according to claim 1, wherein (b) is one or more germicidal compounds selected from the compounds represented by the following general formulas (1) to (3). Embedded image [Wherein, R 1 and R 6 each independently represent a carbon number of 6 to 1 ;
8 alkyl or alkenyl groups, and R 3 and R
4 is independently an alkyl group or a hydroxyalkyl group having 1 to 3 carbon atoms. X is an aromatic ring or -COO
—, —CONH—, —OCO—, or —NHCO—, an ester group or an amide group, and R 2 represents a carbon number which may be substituted with a hydroxyl group when X is an ester group or an amide group. 1 to 6 alkylene groups;
Is an aromatic ring, it is an alkylene group having 1 to 6 carbon atoms which may be substituted with a hydroxyl group, or-(OR 11 ) k- . Here, R 11 is an ethylene group or a propylene group,
k is a number of 1 to 10 on average. R 5 is an alkylene group having 1 to 3 carbon atoms. In R 7 to R 10 , at least one of them is an alkyl group having 8 to 18 carbon atoms, and the rest is a C 1 to C 1 alkyl group.
3 alkyl groups or hydroxyalkyl groups. M is a number of 0 or 1. Further, Y is an anion. ]
【請求項3】 (a)の4級アンモニウム基を有するモ
ノマー単位が、下記一般式(4)の化合物に由来する請
求項1記載の硬質表面用殺菌防汚剤。 【化2】 〔式中、R12、R13、R14は、それぞれ独立して、水素
原子、水酸基又は炭素数1〜3のアルキル基である。X
は炭素数1〜12のアルキレン基、−COOR18−、−
CONHR18−、−OCOR18−、−R19−OCO−R
18−から選ばれる基である。ここでR18、R19は、それ
ぞれ独立して、炭素数1〜5のアルキレン基である。R
15は炭素数1〜3のアルキル基もしくはヒドロキシアル
キル基又はR1213C=C(R14)−X−である。R16
炭素数1〜3のアルキル基、ヒドロキシアルキル基、ベ
ンジル基であり、R17はヒドロキシ基、カルボキシル
基、スルホン酸基もしくは硫酸エステル基で置換されて
いてもよい炭素数1〜10のアルキル基又はベンジル基
であり、R17がアルキル基、ヒドロキシアルキル基又は
ベンジル基の場合は、Y-は陰イオンを示す。また、R
17がカルボキシル基、スルホン酸基、硫酸エステル基を
含む場合、Y-は存在せず、R17中のこれらの基は陰イ
オンとなる。〕
3. The disinfectant / fouling agent for hard surfaces according to claim 1, wherein the monomer unit having a quaternary ammonium group in (a) is derived from a compound represented by the following general formula (4). Embedded image [In the formula, R 12 , R 13 , and R 14 are each independently a hydrogen atom, a hydroxyl group, or an alkyl group having 1 to 3 carbon atoms. X
Is an alkylene group having 1 to 12 carbon atoms, -COOR 18 -,-
CONHR 18 -, - OCOR 18 - , - R 19 -OCO-R
18- . Here, R 18 and R 19 are each independently an alkylene group having 1 to 5 carbon atoms. R
15 hydroxy or alkyl group having 1 to 3 carbon atoms alkyl or R 12 R 13 C = C ( R 14) is -X-. R 16 is an alkyl group having 1 to 3 carbon atoms, a hydroxyalkyl group, or a benzyl group; and R 17 has 1 to 10 carbon atoms which may be substituted with a hydroxy group, a carboxyl group, a sulfonic acid group or a sulfate group. When R 17 is an alkyl group, a hydroxyalkyl group or a benzyl group, Y represents an anion. Also, R
When 17 contains a carboxyl group, a sulfonic acid group, or a sulfate group, Y 2 - is not present, and these groups in R 17 become anions. ]
【請求項4】 更に(c)として、(b)以外の界面活
性剤を0.01重量%以上20重量%未満(但し、組成
物中の陰イオン界面活性剤及びベタイン型両性界面活性
剤の合計量は5.0重量%を超えない)の濃度で含有す
る請求項1〜3何れか一項記載の硬質表面用殺菌防汚洗
浄剤。
4. Further, as (c), 0.01% by weight or more and less than 20% by weight of a surfactant other than (b) (provided that an anionic surfactant and a betaine-type amphoteric surfactant in the composition are used). The germicidal and antifouling detergent for hard surfaces according to any one of claims 1 to 3, which is contained at a concentration of not more than 5.0% by weight.
JP2000252284A 2000-08-23 2000-08-23 Germicidal stainproofing agent for hard surface Pending JP2002060786A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2000252284A JP2002060786A (en) 2000-08-23 2000-08-23 Germicidal stainproofing agent for hard surface
PCT/JP2001/006869 WO2002016536A1 (en) 2000-08-23 2001-08-09 Bactericidal antifouling detergent for hard surface
TW90120399A TWI283267B (en) 2000-08-23 2001-08-20 Bactericidal antifouling detergent for hard surface

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000252284A JP2002060786A (en) 2000-08-23 2000-08-23 Germicidal stainproofing agent for hard surface

Publications (1)

Publication Number Publication Date
JP2002060786A true JP2002060786A (en) 2002-02-26

Family

ID=18741548

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000252284A Pending JP2002060786A (en) 2000-08-23 2000-08-23 Germicidal stainproofing agent for hard surface

Country Status (3)

Country Link
JP (1) JP2002060786A (en)
TW (1) TWI283267B (en)
WO (1) WO2002016536A1 (en)

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004075789A (en) * 2002-08-14 2004-03-11 Kao Corp Cleanser composition for hard surface
JP2004155803A (en) * 2002-11-01 2004-06-03 Kao Corp Solid cleaning agent composition for flush toilet
JP2005029756A (en) * 2003-07-11 2005-02-03 Kao Corp Detergent used for toilet
JP2005029754A (en) * 2003-07-11 2005-02-03 Kao Corp Aqueous liquid composition
WO2008054009A1 (en) 2006-10-31 2008-05-08 Kao Corporation Bleaching agent composition
JP2008266375A (en) * 2007-04-17 2008-11-06 Johnson Diversey Co Ltd Detergent composition for hard surface
JP2010168428A (en) * 2009-01-20 2010-08-05 Kao Corp Liquid detergent composition for hard surface
JP2011246677A (en) * 2010-05-31 2011-12-08 Ueno Fine Chem Ind Ltd Cleaning-sterilizing agent composition
JP2012092320A (en) * 2010-09-28 2012-05-17 Kobayashi Pharmaceutical Co Ltd Biofilm removing agent, composition for removing biofilm, and method for removing biofilm
JP2012111846A (en) * 2010-11-25 2012-06-14 Dainippon Jochugiku Co Ltd Acidic antibacterial detergent composition
JP2012193287A (en) * 2011-03-17 2012-10-11 Adeka Corp Detergent composition for oil stain
JP2012255073A (en) * 2011-06-08 2012-12-27 Kao Corp Liquid detergent composition for hard surface
JP2013023642A (en) * 2011-07-25 2013-02-04 Dainippon Jochugiku Co Ltd Rinse accelerator for hard surface detergent
JP2014009349A (en) * 2012-07-03 2014-01-20 Kao Corp Liquid aroma composition for flush toilet
JP2015507676A (en) * 2011-12-29 2015-03-12 バイオトロル・ピーエルシー Antimicrobial composition
JP2015113455A (en) * 2013-12-16 2015-06-22 花王株式会社 Sterilizing detergent composition for hard surfaces
JP2016124965A (en) * 2014-12-26 2016-07-11 ライオン株式会社 Liquid detergent for bath room
JP2017048238A (en) * 2010-12-31 2017-03-09 バイオトロル・ピーエルシー Antimicrobial composition
JP2019156999A (en) * 2018-03-14 2019-09-19 株式会社ニイタカ Detergent composition, spray bottle, wet wiper, and deodorization and sterilization cleaning method
WO2019199886A1 (en) * 2018-04-09 2019-10-17 Rhodia Operations Compositions and methods for long lasting disinfection
JP2020041074A (en) * 2018-09-12 2020-03-19 ライオン株式会社 Liquid detergent composition for clothing
JP2020100691A (en) * 2018-12-20 2020-07-02 中国塗料株式会社 Antifouling coat composition, antifouling coat film, base material with antifouling coat film, antifouling method for base material and method for producing base material with antifouling coat film
JP2020152856A (en) * 2019-03-22 2020-09-24 株式会社Adeka Detergent composition for rigid surface, and method of cleaning rigid surface

Families Citing this family (272)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4230153B2 (en) * 2002-02-22 2009-02-25 花王株式会社 Antifouling cleaner for hard surfaces
WO2003070867A1 (en) 2002-02-22 2003-08-28 Kao Corporation Antifouling detergent for hard surfaces
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US20120196370A1 (en) 2010-12-03 2012-08-02 Fyodor Urnov Methods and compositions for targeted genomic deletion
EP3222715A1 (en) 2003-08-08 2017-09-27 Sangamo BioSciences, Inc. Methods and compositions for targeted cleavage and recombination
JP2005232241A (en) * 2004-02-18 2005-09-02 Toyo Aluminium Foil Products Kk Coating agent for removing greasy dirt
CA2579677A1 (en) 2004-09-16 2006-03-30 Sangamo Biosciences, Inc. Compositions and methods for protein production
KR101419729B1 (en) 2005-07-26 2014-07-17 상가모 바이오사이언스 인코포레이티드 Targeted integration and expression of exogenous nucleic acid sequences
WO2007139982A2 (en) 2006-05-25 2007-12-06 Sangamo Biosciences, Inc. Methods and compositions for gene inactivation
WO2007139898A2 (en) 2006-05-25 2007-12-06 Sangamo Biosciences, Inc. Variant foki cleavage half-domains
PL2049663T3 (en) 2006-08-11 2015-08-31 Dow Agrosciences Llc Zinc finger nuclease-mediated homologous recombination
US9217026B2 (en) 2006-11-13 2015-12-22 Sangamo Biosciences, Inc. Method of inactivating a glucocorticoid receptor gene in an isolated cell
SI2415872T1 (en) 2006-12-14 2016-09-30 Dow Agrosciences Llc Optimized non-canonical zinc finger proteins
CN101679977B (en) 2007-04-26 2013-05-01 桑格摩生物科学股份有限公司 Targeted integration into the PPP1R12C locus
KR101510778B1 (en) 2007-07-12 2015-04-10 상가모 바이오사이언스 인코포레이티드 Methods and compositions for inactivating alpha 1,6 fucosyltransferase (fut8) gene expression
EP2205749B1 (en) 2007-09-27 2016-05-18 Dow AgroSciences LLC Engineered zinc finger proteins targeting 5-enolpyruvyl shikimate-3-phosphate synthase genes
US8563314B2 (en) 2007-09-27 2013-10-22 Sangamo Biosciences, Inc. Methods and compositions for modulating PD1
US11235026B2 (en) 2007-09-27 2022-02-01 Sangamo Therapeutics, Inc. Methods and compositions for modulating PD1
CA2700231C (en) 2007-09-27 2018-09-18 Sangamo Biosciences, Inc. Rapid in vivo identification of biologically active nucleases
EP2597155B1 (en) 2007-10-25 2016-11-23 Sangamo BioSciences, Inc. Methods and compositions for targeted integration
EP2281050B1 (en) 2008-04-14 2014-04-02 Sangamo BioSciences, Inc. Linear donor constructs for targeted integration
US8791324B2 (en) 2008-04-21 2014-07-29 Danziger Innovations Ltd. Plant viral expression vectors and use of same for generating genotypic variations in plant genomes
JP2011521643A (en) 2008-05-28 2011-07-28 サンガモ バイオサイエンシーズ, インコーポレイテッド Composition for linking a DNA binding domain and a cleavage domain
KR101802393B1 (en) 2008-06-10 2017-11-28 상가모 테라퓨틱스, 인코포레이티드 Methods and compositions for generation of bax- and bak-deficient cell lines
CN102159722B (en) 2008-08-22 2014-09-03 桑格摩生物科学股份有限公司 Methods and compositions for targeted single-stranded cleavage and targeted integration
AU2009311697B2 (en) 2008-10-29 2014-12-18 Sangamo Therapeutics, Inc. Methods and compositions for inactivating glutamine synthetase gene expression
KR101803737B1 (en) 2008-12-04 2017-12-01 상가모 테라퓨틱스, 인코포레이티드 Genome editing in rats using zinc-finger nucleases
AR074783A1 (en) 2008-12-17 2011-02-09 Dow Agrosciences Llc METHODS AND COMPOSITIONS TO EXPRESS ONE OR MORE PRODUCTS OF A NUCLEIC ACID INTEGRATED TO LOCUS ZP15 OF A VEGETABLE CELL
CA2934285C (en) 2009-02-04 2018-11-27 Sangamo Biosciences, Inc. Methods and compositions for treating neuropathies
CA2755192C (en) 2009-03-20 2018-09-11 Sangamo Biosciences, Inc. Modification of cxcr4 using engineered zinc finger proteins
CA2756833C (en) 2009-04-09 2019-11-19 Sangamo Biosciences, Inc. Targeted integration into stem cells
US8772008B2 (en) 2009-05-18 2014-07-08 Sangamo Biosciences, Inc. Methods and compositions for increasing nuclease activity
AU2010266705B2 (en) 2009-06-30 2014-06-05 Sangamo Therapeutics, Inc. Rapid screening of biologically active nucleases and isolation of nuclease-modified cells
US9234016B2 (en) 2009-07-28 2016-01-12 Sangamo Biosciences, Inc. Engineered zinc finger proteins for treating trinucleotide repeat disorders
WO2011019385A1 (en) 2009-08-11 2011-02-17 Sangamo Biosciences, Inc. Organisms homozygous for targeted modification
WO2011048600A1 (en) 2009-10-21 2011-04-28 Danziger Innovations Ltd. Generating genotypic variations in plant genomes by gamete infection
MY174390A (en) 2009-10-22 2020-04-15 Sangamo Biosciences Inc Engineered zinc finger proteins targeting plant genes involved in fatty acid biosynthesis
US8956828B2 (en) 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
EA031322B1 (en) 2010-01-22 2018-12-28 Дау Агросайенсиз Ллс Cell or cell line for expression of exogenous nucleic acid sequences and use of a cell or cell line
CA2788560A1 (en) 2010-02-08 2011-08-11 Sangamo Biosciences, Inc. Engineered cleavage half-domains
US9255259B2 (en) 2010-02-09 2016-02-09 Sangamo Biosciences, Inc. Targeted genomic modification with partially single-stranded donor molecules
CA2796600C (en) 2010-04-26 2019-08-13 Sangamo Biosciences, Inc. Genome editing of a rosa locus using zinc-finger nucleases
WO2011139349A1 (en) 2010-05-03 2011-11-10 Sangamo Biosciences, Inc. Compositions for linking zinc finger modules
AU2011281062B2 (en) 2010-07-21 2015-01-22 Board Of Regents, The University Of Texas System Methods and compositions for modification of a HLA locus
WO2012047598A1 (en) 2010-09-27 2012-04-12 Sangamo Biosciences, Inc. Methods and compositions for inhibiting viral entry into cells
CA2814143C (en) 2010-10-12 2020-09-08 The Children's Hospital Of Philadelphia Methods and compositions for treating hemophilia b
US9267123B2 (en) 2011-01-05 2016-02-23 Sangamo Biosciences, Inc. Methods and compositions for gene correction
JP6072788B2 (en) 2011-07-25 2017-02-01 サンガモ バイオサイエンシーズ, インコーポレイテッド Methods and compositions for altering the cystic fibrosis membrane conductance regulator (CFTR) gene
CN103917644A (en) 2011-09-21 2014-07-09 桑格摩生物科学股份有限公司 Methods and compositions for regulation of transgene expression
EP2771457B1 (en) 2011-10-27 2017-11-22 Sangamo Therapeutics, Inc. Methods and compositions for modification of the hprt locus
CA2854819C (en) 2011-11-16 2022-07-19 Sangamo Biosciences, Inc. Modified dna-binding proteins and uses thereof
JP6490426B2 (en) 2012-02-29 2019-03-27 サンガモ セラピューティクス, インコーポレイテッド Methods and compositions for treating Huntington's disease
DK2839013T3 (en) 2012-04-18 2020-09-14 Univ Leland Stanford Junior NON-DISRUPTIVE-GEN-TARGETING
EP2841572B1 (en) 2012-04-27 2019-06-19 Duke University Genetic correction of mutated genes
MX369788B (en) 2012-05-02 2019-11-21 Dow Agrosciences Llc Targeted modification of malate dehydrogenase.
RU2650819C2 (en) 2012-05-07 2018-04-17 Сангамо Терапьютикс, Инк. Methods and compositions for nuclease-mediated targeting of transgenes
CA2878037C (en) 2012-07-11 2021-08-31 Sangamo Biosciences, Inc. Methods and compositions for delivery of biologics
US10648001B2 (en) 2012-07-11 2020-05-12 Sangamo Therapeutics, Inc. Method of treating mucopolysaccharidosis type I or II
HUE041553T2 (en) 2012-07-11 2019-05-28 Sangamo Therapeutics Inc Methods and compositions for the treatment of monogenic diseases
ES2812599T3 (en) 2012-08-29 2021-03-17 Sangamo Therapeutics Inc Procedures and compositions for the treatment of a genetic condition
UA119135C2 (en) 2012-09-07 2019-05-10 ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі Engineered transgene integration platform (etip) for gene targeting and trait stacking
CN105264067B (en) 2012-09-07 2020-11-10 美国陶氏益农公司 FAD3 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
UA118090C2 (en) 2012-09-07 2018-11-26 ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі Fad2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
ES2824024T3 (en) 2012-10-10 2021-05-11 Sangamo Therapeutics Inc T cell modifying compounds and uses thereof
US9255250B2 (en) 2012-12-05 2016-02-09 Sangamo Bioscience, Inc. Isolated mouse or human cell having an exogenous transgene in an endogenous albumin gene
KR20150096696A (en) 2012-12-13 2015-08-25 다우 아그로사이언시즈 엘엘씨 Precision gene targeting to a particular locus in maize
AU2014218621B2 (en) 2013-02-25 2019-11-07 Sangamo Therapeutics, Inc. Methods and compositions for enhancing nuclease-mediated gene disruption
US9937207B2 (en) 2013-03-21 2018-04-10 Sangamo Therapeutics, Inc. Targeted disruption of T cell receptor genes using talens
CN105263312A (en) 2013-04-05 2016-01-20 美国陶氏益农公司 Methods and compositions for integration of an exogenous sequence within the genome of plants
CA2910489A1 (en) 2013-05-15 2014-11-20 Sangamo Biosciences, Inc. Methods and compositions for treatment of a genetic condition
CA2920899C (en) 2013-08-28 2023-02-28 Sangamo Biosciences, Inc. Compositions for linking dna-binding domains and cleavage domains
CN105899665B (en) 2013-10-17 2019-10-22 桑格摩生物科学股份有限公司 The delivering method and composition being transformed for nuclease-mediated genome project
WO2015057976A1 (en) 2013-10-17 2015-04-23 Sangamo Biosciences, Inc. Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells
UA120503C2 (en) 2013-11-04 2019-12-26 Дау Агросайєнсиз Елелсі Optimal maize loci
UY35816A (en) 2013-11-04 2015-05-29 Dow Agrosciences Llc ? OPTIMAL SOY LOCUS ?.
AU2014341929B2 (en) 2013-11-04 2017-11-30 Corteva Agriscience Llc Optimal maize loci
WO2015066634A2 (en) 2013-11-04 2015-05-07 Dow Agrosciences Llc Optimal soybean loci
BR112016010175A2 (en) 2013-11-11 2017-10-03 Sangamo Biosciences Inc GENETIC REPRESSOR, ITS USES, AND PHARMACEUTICAL COMPOSITION
EP3960856A1 (en) 2013-11-13 2022-03-02 Children's Medical Center Corporation Nuclease-mediated regulation of gene expression
US9932607B2 (en) 2013-11-15 2018-04-03 The Board Of Trustees Of The Leland Stanford Junior University Site-specific integration of transgenes into human cells
EP3757116A1 (en) 2013-12-09 2020-12-30 Sangamo Therapeutics, Inc. Methods and compositions for genome engineering
PL3102673T3 (en) 2014-02-03 2020-11-02 Sangamo Therapeutics, Inc. Methods and compositions for treatment of a beta thalessemia
JP6606088B2 (en) 2014-02-24 2019-11-13 サンガモ セラピューティクス, インコーポレイテッド Methods and compositions for nuclease-mediated targeted integration
TW201538518A (en) 2014-02-28 2015-10-16 Dow Agrosciences Llc Root specific expression conferred by chimeric gene regulatory elements
US9624498B2 (en) 2014-03-18 2017-04-18 Sangamo Biosciences, Inc. Methods and compositions for regulation of zinc finger protein expression
AU2015231231B2 (en) 2014-03-21 2021-09-02 The Board Of Trustees Of The Leland Stanford Junior University Genome editing without nucleases
WO2015153889A2 (en) 2014-04-02 2015-10-08 University Of Florida Research Foundation, Incorporated Materials and methods for the treatment of latent viral infection
MX2016014565A (en) 2014-05-08 2017-05-23 Sangamo Biosciences Inc Methods and compositions for treating huntington's disease.
CA2947622A1 (en) 2014-05-13 2015-11-19 Sangamo Biosciences, Inc. Genome editing methods and compositions for prevention or treatment of a disease
US9970001B2 (en) 2014-06-05 2018-05-15 Sangamo Therapeutics, Inc. Methods and compositions for nuclease design
US20170159065A1 (en) 2014-07-08 2017-06-08 Vib Vzw Means and methods to increase plant yield
CA2955203C (en) 2014-07-14 2022-01-04 Washington State University Nanos knock-out that ablates germline cells
WO2016011210A2 (en) 2014-07-15 2016-01-21 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
US11278572B2 (en) 2014-07-18 2022-03-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Reducing CXCR4 expression and/or function to enhance engraftment of hematopoietic stem cells
WO2016014837A1 (en) 2014-07-25 2016-01-28 Sangamo Biosciences, Inc. Gene editing for hiv gene therapy
US9816074B2 (en) 2014-07-25 2017-11-14 Sangamo Therapeutics, Inc. Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells
US9616090B2 (en) 2014-07-30 2017-04-11 Sangamo Biosciences, Inc. Gene correction of SCID-related genes in hematopoietic stem and progenitor cells
ES2886012T3 (en) 2014-09-16 2021-12-16 Sangamo Therapeutics Inc Methods and compositions for nuclease-mediated genome engineering and correction in hematopoietic stem cells
US10889834B2 (en) 2014-12-15 2021-01-12 Sangamo Therapeutics, Inc. Methods and compositions for enhancing targeted transgene integration
EP3247366A4 (en) 2015-01-21 2018-10-31 Sangamo Therapeutics, Inc. Methods and compositions for identification of highly specific nucleases
US10626372B1 (en) 2015-01-26 2020-04-21 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
EP3256487A4 (en) 2015-02-09 2018-07-18 Duke University Compositions and methods for epigenome editing
ES2959608T3 (en) 2015-04-03 2024-02-27 Dana Farber Cancer Inst Inc Composition and editing methods of the B cell genome
JP2018511331A (en) 2015-04-15 2018-04-26 ダウ アグロサイエンシィズ エルエルシー Plant promoter for transgene expression
MX2017012936A (en) 2015-04-15 2018-02-01 Dow Agrosciences Llc Plant promoter for transgene expression.
CN108026566A (en) 2015-05-04 2018-05-11 特拉维夫大学拉莫特有限公司 For making the method and kit of DNA fragmentation
US10179918B2 (en) 2015-05-07 2019-01-15 Sangamo Therapeutics, Inc. Methods and compositions for increasing transgene activity
US10808020B2 (en) 2015-05-12 2020-10-20 Sangamo Therapeutics, Inc. Nuclease-mediated regulation of gene expression
CA2986060A1 (en) 2015-05-29 2016-12-08 Valerie Odegard Composition and methods for regulating inhibitory interactions in genetically engineered cells
US9957501B2 (en) 2015-06-18 2018-05-01 Sangamo Therapeutics, Inc. Nuclease-mediated regulation of gene expression
AU2016291778B2 (en) 2015-07-13 2021-05-06 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
MA42895A (en) 2015-07-15 2018-05-23 Juno Therapeutics Inc MODIFIED CELLS FOR ADOPTIVE CELL THERAPY
WO2017023570A1 (en) 2015-08-06 2017-02-09 The Curators Of The University Of Missouri Pathogen-resistant animals having modified cd163 genes
TW201718862A (en) 2015-09-22 2017-06-01 Dow Agrosciences Llc Plant promoter and 3' UTR for transgene expression
TW201718861A (en) 2015-09-22 2017-06-01 道禮責任有限公司 Plant promoter and 3'UTR for transgene expression
EA037993B1 (en) 2015-09-23 2021-06-21 Сангамо Терапьютикс, Инк. Htt repressors and uses thereof
US11970710B2 (en) 2015-10-13 2024-04-30 Duke University Genome engineering with Type I CRISPR systems in eukaryotic cells
CA3002151A1 (en) 2015-10-22 2017-04-27 Dow Agrosciences Llc Plant promoter for transgene expression
CN108368520B (en) 2015-11-04 2023-01-17 菲特治疗公司 Genome engineering of pluripotent cells
US20170121726A1 (en) 2015-11-04 2017-05-04 Dow Agrosciences Llc Plant promoter for transgene expression
CA3003152A1 (en) 2015-11-04 2017-05-11 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
CA3004349A1 (en) 2015-11-23 2017-06-01 Sangamo Therapeutics, Inc. Methods and compositions for engineering immunity
AU2016369490C1 (en) 2015-12-18 2021-12-23 Sangamo Therapeutics, Inc. Targeted disruption of the T cell receptor
CN108699132B (en) 2015-12-18 2023-08-11 桑格摩生物治疗股份有限公司 Targeted disruption of MHC cell receptors
EP3402533B1 (en) 2016-01-15 2021-08-04 Sangamo Therapeutics, Inc. Methods and compositions for the treatment of neurologic disease
CN109069568B (en) 2016-02-02 2023-07-07 桑格摩生物治疗股份有限公司 Compositions for linking DNA binding domains and cleavage domains
AU2017238512B2 (en) 2016-03-23 2022-12-08 Dana-Farber Cancer Institute, Inc. Methods for enhancing the efficiency of gene editing
EP3475446A1 (en) 2016-06-27 2019-05-01 Juno Therapeutics, Inc. Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
MA45491A (en) 2016-06-27 2019-05-01 Juno Therapeutics Inc CMH-E RESTRICTED EPITOPES, BINDING MOLECULES AND RELATED METHODS AND USES
US11124805B2 (en) 2016-07-13 2021-09-21 Vertex Pharmaceuticals Incorporated Methods, compositions and kits for increasing genome editing efficiency
US11344511B2 (en) 2016-07-27 2022-05-31 Case Western Reserve University Compounds and methods of promoting myelination
US11193136B2 (en) 2016-08-09 2021-12-07 Vib Vzw Cellulose synthase inhibitors and mutant plants
WO2018039440A1 (en) 2016-08-24 2018-03-01 Sangamo Therapeutics, Inc. Regulation of gene expression using engineered nucleases
AU2017315414B2 (en) 2016-08-24 2024-02-15 Sangamo Therapeutics, Inc. Engineered target specific nucleases
WO2018049009A2 (en) 2016-09-07 2018-03-15 Sangamo Therapeutics, Inc. Modulation of liver genes
MX2019003768A (en) 2016-10-03 2019-06-24 Juno Therapeutics Inc Hpv-specific binding molecules.
EP3518657B1 (en) 2016-10-03 2022-07-13 Corteva Agriscience LLC Plant promoter for transgene expression
CN110291199B (en) 2016-10-03 2023-12-22 美国陶氏益农公司 Plant promoters for transgene expression
US10961505B2 (en) 2016-10-05 2021-03-30 FUJIFILM Cellular Dynamics, Inc. Generating mature lineages from induced pluripotent stem cells with MECP2 disruption
CN110381963A (en) 2016-10-13 2019-10-25 朱诺治疗学股份有限公司 It is related to the immunotherapy method and composition of tryptophan metabolic pathway regulator
CA3039673A1 (en) 2016-10-20 2018-04-26 Sangamo Therapeutics, Inc. Methods and compositions for the treatment of fabry disease
US11020492B2 (en) 2016-10-31 2021-06-01 Sangamo Therapeutics, Inc. Gene correction of SCID-related genes in hematopoietic stem and progenitor cells
IL266862B2 (en) 2016-12-01 2024-01-01 Sangamo Therapeutics Inc Tau modulators and methods and compositions for delivery thereof
CA3045323A1 (en) 2016-12-02 2018-06-07 Juno Therapeutics, Inc. Engineered b cells and related compositions and methods
BR112019011207A2 (en) 2016-12-05 2019-10-08 Juno Therapeutics Inc modified cell production for adoptive cell therapy
JP7416406B2 (en) 2016-12-08 2024-01-17 ケース ウェスタン リザーブ ユニバーシティ Methods and compositions for increasing functional myelin production
EP3585895A1 (en) 2017-02-22 2020-01-01 CRISPR Therapeutics AG Compositions and methods for gene editing
SG11201906948UA (en) 2017-04-20 2019-08-27 Univ Oregon Health & Science Human gene correction
AU2018261366A1 (en) 2017-05-03 2019-10-31 Sangamo Therapeutics, Inc. Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (CTFR) gene
US11512287B2 (en) 2017-06-16 2022-11-29 Sangamo Therapeutics, Inc. Targeted disruption of T cell and/or HLA receptors
EP4215543A3 (en) 2017-10-03 2023-10-11 Juno Therapeutics, Inc. Hpv-specific binding molecules
US11851679B2 (en) 2017-11-01 2023-12-26 Juno Therapeutics, Inc. Method of assessing activity of recombinant antigen receptors
US11661611B2 (en) 2017-11-09 2023-05-30 Sangamo Therapeutics, Inc. Genetic modification of cytokine inducible SH2-containing protein (CISH) gene
SG11202005173SA (en) 2017-12-22 2020-06-29 Fate Therapeutics Inc Enhanced immune effector cells and use thereof
BR112020014140A2 (en) 2018-01-17 2020-12-01 Vertex Pharmaceuticals Incorporated dna-pk inhibitors
AU2019209293B2 (en) 2018-01-17 2023-07-27 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
WO2019143677A1 (en) 2018-01-17 2019-07-25 Vertex Pharmaceuticals Incorporated Quinoxalinone compounds, compositions, methods, and kits for increasing genome editing efficiency
BR112020015488A2 (en) 2018-02-08 2020-12-08 Sangamo Therapeutics, Inc. MODIFIED TARGET-SPECIFIC NUCLEASES
WO2019191495A1 (en) 2018-03-29 2019-10-03 Fate Therapeutics, Inc. Engineered immune effector cells and use thereof
RU2020136054A (en) 2018-04-05 2022-05-06 Джуно Терапьютикс, Инк. T-CELLS EXPRESSING RECOMBINANT RECEPTOR, CORRESPONDING POLYNUCLEOTIDES AND METHODS
EP3773908A1 (en) 2018-04-05 2021-02-17 Juno Therapeutics, Inc. T cell receptors and engineered cells expressing same
BR112020020245A2 (en) 2018-04-05 2021-04-06 Editas Medicine, Inc. METHODS OF PRODUCING CELLS EXPRESSING A RECOMBINANT RECEIVER AND RELATED COMPOSITIONS
EP3781587A4 (en) 2018-04-18 2022-03-30 Sangamo Therapeutics, Inc. Zinc finger protein compositions for modulation of huntingtin (htt)
EP3790629A1 (en) 2018-05-11 2021-03-17 CRISPR Therapeutics AG Methods and compositions for treating cancer
US11690921B2 (en) 2018-05-18 2023-07-04 Sangamo Therapeutics, Inc. Delivery of target specific nucleases
GB201809273D0 (en) 2018-06-06 2018-07-25 Vib Vzw Novel mutant plant cinnamoyl-coa reductase proteins
CA3102975A1 (en) 2018-06-07 2019-12-12 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Methods of regenerating and transforming cannabis
EP3802839A1 (en) 2018-06-07 2021-04-14 The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center) Nucleic acid constructs and methods of using same
SG11202101801RA (en) 2018-08-23 2021-03-30 Sangamo Therapeutics Inc Engineered target specific base editors
CN113015741A (en) 2018-09-18 2021-06-22 桑格摩生物治疗股份有限公司 Programmed cell death 1(PD1) specific nucleases
SG11202103832SA (en) 2018-11-07 2021-05-28 Crispr Therapeutics Ag Anti-cd33 immune cell cancer therapy
CN113015750A (en) 2018-11-07 2021-06-22 克里斯珀医疗股份公司 anti-LIV 1 immune cell cancer therapy
US20210290678A1 (en) 2018-11-07 2021-09-23 Crispr Therapeutics Ag Anti-ptk7 immune cell cancer therapy
BR112021010753A2 (en) 2018-12-05 2021-09-21 Vertex Pharmaceuticals Incorporated GENE EDITING SYSTEMS TO EDIT A CYSTIC FIBROSIS TRANS MEMBRANE REGULATORY GENE (CFTR)
GB201820109D0 (en) 2018-12-11 2019-01-23 Vib Vzw Plants with a lignin trait and udp-glycosyltransferase mutation
US11453639B2 (en) 2019-01-11 2022-09-27 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
EP3826664A4 (en) 2019-02-06 2022-10-26 Sangamo Therapeutics, Inc. Method for the treatment of mucopolysaccharidosis type i
US20220175781A1 (en) 2019-03-08 2022-06-09 Obsidian Therapeutics, Inc. Cd40l compositions and methods for tunable regulation
EP3946384A1 (en) 2019-04-02 2022-02-09 Sangamo Therapeutics, Inc. Methods for the treatment of beta-thalassemia
EP3958871A1 (en) 2019-04-23 2022-03-02 Sangamo Therapeutics, Inc. Modulators of chromosome 9 open reading frame 72 gene expression and uses thereof
AU2020265741A1 (en) 2019-05-01 2021-11-25 Editas Medicine, Inc. Cells expressing a recombinant receptor from a modified TGFBR2 Locus, related polynucleotides and methods
KR20220016474A (en) 2019-05-01 2022-02-09 주노 쎄러퓨티크스 인코퍼레이티드 Cells expressing chimeric receptors from modified CD247 loci, related polynucleotides and methods
JP2022538836A (en) 2019-06-27 2022-09-06 クリスパー セラピューティクス アクチェンゲゼルシャフト Use of chimeric antigen receptor T cells and NK cell inhibitors to treat cancer
WO2021022223A1 (en) 2019-08-01 2021-02-04 Sana Biotechnology, Inc. Dux4 expressing cells and uses thereof
AU2020336302A1 (en) 2019-08-23 2022-03-03 Sana Biotechnology, Inc. CD24 expressing cells and uses thereof
BR112022003891A2 (en) 2019-09-06 2022-05-31 Crispr Therapeutics Ag Genetically engineered t cells having improved persistence in culture
WO2021067864A1 (en) 2019-10-02 2021-04-08 Sangamo Therapeutics, Inc. Zinc finger protein transcription factors for treatment of prion disease
KR20220071248A (en) 2019-10-02 2022-05-31 상가모 테라퓨틱스, 인코포레이티드 Zinc finger protein transcription factor to inhibit alpha-synuclein expression
TW202132566A (en) 2019-11-01 2021-09-01 美商聖加莫治療股份有限公司 Zinc finger nuclease variants for treating or preventing lysosomal storage diseases
WO2021087358A1 (en) 2019-11-01 2021-05-06 Sangamo Therapeutics, Inc. Gin recombinase variants
EP4087861A1 (en) 2020-01-08 2022-11-16 Obsidian Therapeutics, Inc. Compositions and methods for tunable regulation of transcription
CN115210251A (en) 2020-01-22 2022-10-18 桑格摩生物治疗股份有限公司 Zinc finger protein transcription factor for repressing TAU expression
WO2021155065A1 (en) 2020-01-28 2021-08-05 The Broad Institute, Inc. Base editors, compositions, and methods for modifying the mitochondrial genome
US20230293593A1 (en) 2020-03-25 2023-09-21 Sana Biotechnology, Inc. Hypoimmunogenic neural cells for the treatment of neurological disorders and conditions
JP2023525510A (en) 2020-05-06 2023-06-16 セレクティス ソシエテ アノニム Methods of genetically modifying cells for delivery of therapeutic proteins
JP2023525513A (en) 2020-05-06 2023-06-16 セレクティス ソシエテ アノニム Methods for targeted insertion of exogenous sequences in the cellular genome
WO2021231661A2 (en) 2020-05-13 2021-11-18 Juno Therapeutics, Inc. Process for producing donor-batched cells expressing a recombinant receptor
US20230190871A1 (en) 2020-05-20 2023-06-22 Sana Biotechnology, Inc. Methods and compositions for treatment of viral infections
WO2021247836A1 (en) 2020-06-03 2021-12-09 Board Of Regents, The University Of Texas System Methods for targeting shp-2 to overcome resistance
EP4171616A1 (en) 2020-06-26 2023-05-03 Juno Therapeutics GmbH Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
JP2023535365A (en) 2020-07-16 2023-08-17 アクイタス セラピューティクス インコーポレイテッド Cationic lipids for use in lipid nanoparticles
KR20230074718A (en) 2020-08-13 2023-05-31 사나 바이오테크놀로지, 인크. Methods of treating patients sensitized with hypoimmunogenic cells and related methods and compositions
WO2022046760A2 (en) 2020-08-25 2022-03-03 Kite Pharma, Inc. T cells with improved functionality
EP4176048A1 (en) 2020-09-23 2023-05-10 CRISPR Therapeutics AG Genetically engineered t cells with regnase-1 and/or tgfbrii disruption have improved functionality and persistence
AU2021350099A1 (en) 2020-09-25 2023-04-27 Sangamo Therapeutics, Inc. Zinc finger fusion proteins for nucleobase editing
US20240018203A1 (en) 2020-10-02 2024-01-18 Sangamo Therapeutics, Inc. Novel zinc finger protein transcription factors for repressing alpha-synuclein expression
CN116802203A (en) 2020-11-04 2023-09-22 朱诺治疗学股份有限公司 Cells expressing chimeric receptors from modified constant CD3 immunoglobulin superfamily chain loci, related polynucleotides and methods
CA3200855A1 (en) 2020-11-16 2022-05-19 Pig Improvement Company Uk Limited Influenza a-resistant animals having edited anp32 genes
MX2023006395A (en) 2020-12-03 2023-06-15 Century Therapeutics Inc Genetically engineered cells and uses thereof.
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
US20220193134A1 (en) 2020-12-23 2022-06-23 Crispr Therapeutics Ag Co-use of lenalidomide with car-t cells
CA3200509A1 (en) 2020-12-31 2022-07-07 Sonja SCHREPFER Methods and compositions for modulating car-t activity
EP4305153A1 (en) 2021-03-09 2024-01-17 CRISPR Therapeutics AG Genetically engineered t cells with ptpn2 knockout have improved functionality and anti-tumor activity
WO2022204071A1 (en) 2021-03-22 2022-09-29 Juno Therapeutics, Inc. Method to assess potency of viral vector particles
CN117479952A (en) 2021-04-07 2024-01-30 世纪治疗股份有限公司 Combined artificial cell death/reporter polypeptides for chimeric antigen receptor cells and uses thereof
CA3214473A1 (en) 2021-04-07 2022-10-13 Century Therapeutics, Inc. Compositions and methods for generating alpha-beta t cells from induced pluripotent stem cells
EP4320227A1 (en) 2021-04-07 2024-02-14 Century Therapeutics, Inc. Compositions and methods for generating gamma-delta t cells from induced pluripotent stem cells
JP2024516992A (en) 2021-05-05 2024-04-18 フジフィルム セルラー ダイナミクス,インコーポレイテッド Methods and Compositions for IPSC-Derived Microglia
KR20240011831A (en) 2021-05-26 2024-01-26 후지필름 셀룰러 다이내믹스, 인코포레이티드 Methods for preventing rapid silencing of genes in pluripotent stem cells
AU2022283291A1 (en) 2021-05-27 2023-11-02 Sana Biotechnology, Inc. Hypoimmunogenic cells comprising engineered hla-e or hla-g
WO2023287827A2 (en) 2021-07-14 2023-01-19 Sana Biotechnology, Inc. Altered expression of y chromosome-linked antigens in hypoimmunogenic cells
AU2022318664A1 (en) 2021-07-30 2024-02-29 Tune Therapeutics, Inc. Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
WO2023010133A2 (en) 2021-07-30 2023-02-02 Tune Therapeutics, Inc. Compositions and methods for modulating expression of frataxin (fxn)
WO2023019226A1 (en) 2021-08-11 2023-02-16 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy
WO2023019229A1 (en) 2021-08-11 2023-02-16 Sana Biotechnology, Inc. Genetically modified primary cells for allogeneic cell therapy
WO2023019227A1 (en) 2021-08-11 2023-02-16 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
CA3227613A1 (en) 2021-08-11 2023-02-16 William Dowdle Inducible systems for altering gene expression in hypoimmunogenic cells
AU2022325955A1 (en) 2021-08-11 2024-02-08 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
KR20240055838A (en) 2021-09-10 2024-04-29 후지필름 셀룰러 다이내믹스, 인코포레이티드 Compositions of cells derived from induced pluripotent stem cells and methods of using the same
US20230128917A1 (en) 2021-09-14 2023-04-27 Crispr Therapeutics Ag Genetically engineered immune cells having a disrupted cd83 gene
AU2022371442A1 (en) 2021-10-21 2024-04-18 Vertex Pharmaceuticals Incorporated Hypoimmune cells
WO2023069790A1 (en) 2021-10-22 2023-04-27 Sana Biotechnology, Inc. Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods
WO2023076880A1 (en) 2021-10-25 2023-05-04 Board Of Regents, The University Of Texas System Foxo1-targeted therapy for the treatment of cancer
US20240034992A1 (en) 2021-10-29 2024-02-01 FUJIFILM Cellular Dynamics, Inc. Dopaminergic neurons comprising mutations and methods of use thereof
WO2023081900A1 (en) 2021-11-08 2023-05-11 Juno Therapeutics, Inc. Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
WO2023105244A1 (en) 2021-12-10 2023-06-15 Pig Improvement Company Uk Limited Editing tmprss2/4 for disease resistance in livestock
WO2023111913A1 (en) 2021-12-15 2023-06-22 Crispr Therapeutics Ag Engineered anti-liv1 cell with regnase-1 and/or tgfbrii disruption
WO2023122722A1 (en) 2021-12-22 2023-06-29 Sangamo Therapeutics, Inc. Novel zinc finger fusion proteins for nucleobase editing
US20230346836A1 (en) 2021-12-22 2023-11-02 Crispr Therapeutics Ag Genetically engineered t cells with disrupted casitas b-lineage lymphoma proto-oncogene-b (cblb) and uses thereof
WO2023122337A1 (en) 2021-12-23 2023-06-29 Sana Biotechnology, Inc. Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methods
WO2023129937A1 (en) 2021-12-29 2023-07-06 Century Therapeutics, Inc. Genetically engineered cells having anti-cd19 / anti-cd22 chimeric antigen receptors, and uses thereof
WO2023131616A1 (en) 2022-01-05 2023-07-13 Vib Vzw Means and methods to increase abiotic stress tolerance in plants
WO2023131637A1 (en) 2022-01-06 2023-07-13 Vib Vzw Improved silage grasses
WO2023137471A1 (en) 2022-01-14 2023-07-20 Tune Therapeutics, Inc. Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation
WO2023137472A2 (en) 2022-01-14 2023-07-20 Tune Therapeutics, Inc. Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression
WO2023144199A1 (en) 2022-01-26 2023-08-03 Vib Vzw Plants having reduced levels of bitter taste metabolites
WO2023154578A1 (en) 2022-02-14 2023-08-17 Sana Biotechnology, Inc. Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
WO2023158836A1 (en) 2022-02-17 2023-08-24 Sana Biotechnology, Inc. Engineered cd47 proteins and uses thereof
TW202340457A (en) 2022-02-28 2023-10-16 美商凱特製藥公司 Allogeneic therapeutic cells
WO2023166425A1 (en) 2022-03-01 2023-09-07 Crispr Therapeutics Ag Methods and compositions for treating angiopoietin-like 3 (angptl3) related conditions
WO2023173123A1 (en) 2022-03-11 2023-09-14 Sana Biotechnology, Inc. Genetically modified cells and compositions and uses thereof
WO2023180904A1 (en) 2022-03-21 2023-09-28 Crispr Therapeutics Ag Methods and compositions for treating lipoprotein-related diseases
WO2023180968A1 (en) 2022-03-23 2023-09-28 Crispr Therapeutics Ag Anti-cd19 car-t cells with multiple gene edits and therapeutic uses thereof
WO2023180967A1 (en) 2022-03-23 2023-09-28 Crispr Therapeutics Ag Anti-cd83 car-t cells with regnase-1 and/or tgfbrii disruption
WO2023230613A1 (en) 2022-05-27 2023-11-30 The Broad Institute, Inc. Improved mitochondrial base editors and methods for editing mitochondrial dna
WO2023240169A1 (en) 2022-06-08 2023-12-14 Century Therapeutics, Inc. Immunoeffector cells derived from induced pluripotent stem cells genetically engineered with membrane bound il12 and uses thereof
WO2023240147A1 (en) 2022-06-08 2023-12-14 Century Therapeutics, Inc. Genetically engineered cells expressing cd16 variants and nkg2d and uses thereof
WO2023240212A2 (en) 2022-06-08 2023-12-14 Century Therapeutics, Inc. Genetically engineered cells having anti-cd133 / anti-egfr chimeric antigen receptors, and uses thereof
WO2023242827A2 (en) 2022-06-17 2023-12-21 Crispr Therapeutics Ag LIPID NANOPARTICLES (LNPs)-BASED OCULAR DELIVERY
WO2023248147A1 (en) 2022-06-21 2023-12-28 Crispr Therapeutics Ag Methods and compositions for in vivo editing of stem cells
WO2023248145A1 (en) 2022-06-21 2023-12-28 Crispr Therapeutics Ag Compositions and methods for treating human immunodeficiency virus
WO2023250511A2 (en) 2022-06-24 2023-12-28 Tune Therapeutics, Inc. Compositions, systems, and methods for reducing low-density lipoprotein through targeted gene repression
WO2024003786A1 (en) 2022-06-29 2024-01-04 Crispr Therapeutics Ag Chimeric antigen receptor targeting gpc-3 and immune cells expressing such for therapeutic uses
WO2024006911A1 (en) 2022-06-29 2024-01-04 FUJIFILM Holdings America Corporation Ipsc-derived astrocytes and methods of use thereof
WO2024015881A2 (en) 2022-07-12 2024-01-18 Tune Therapeutics, Inc. Compositions, systems, and methods for targeted transcriptional activation
WO2024013514A2 (en) 2022-07-15 2024-01-18 Pig Improvement Company Uk Limited Gene edited livestock animals having coronavirus resistance
WO2024023802A2 (en) 2022-07-29 2024-02-01 Crispr Therapeutics Ag Genetically engineered immune cells having disrupted transporter associated with antigen processing-2 (tap-2) gene
WO2024023804A2 (en) 2022-07-29 2024-02-01 Crispr Therapeutics Ag Genetically engineered immune cells having disrupted transporter associated with antigen processing binding protein (tapbp) gene
WO2024023801A2 (en) 2022-07-29 2024-02-01 Crispr Therapeutics Ag Genetically engineered immune cells having disrupted transporter associated with antigen processing-1 (tap-1) gene
US20240067969A1 (en) 2022-08-19 2024-02-29 Tune Therapeutics, Inc. Compositions, systems, and methods for regulation of hepatitis b virus through targeted gene repression
WO2024064642A2 (en) 2022-09-19 2024-03-28 Tune Therapeutics, Inc. Compositions, systems, and methods for modulating t cell function
WO2024062388A2 (en) 2022-09-20 2024-03-28 Crispr Therapeutics Ag Genetically engineered immune cells expressing chimeric antigen receptor targeting cd20

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4014808A (en) * 1973-06-04 1977-03-29 Tennant Company Detergent composition
GB8723776D0 (en) * 1987-10-09 1987-11-11 Procter & Gamble Ltd Toilet compositions
GB8811953D0 (en) * 1988-05-20 1988-06-22 Unilever Plc General-purpose cleaning compositions
JP2523837B2 (en) * 1988-11-25 1996-08-14 花王株式会社 Detergent composition for flush toilet
GB8914462D0 (en) * 1989-06-23 1989-08-09 Unilever Plc Cleaning composition
JP2952555B2 (en) * 1993-12-28 1999-09-27 花王株式会社 Hard surface cleaning composition
JP3347250B2 (en) * 1995-12-20 2002-11-20 花王株式会社 Antifouling detergent composition for toilet
JP3441885B2 (en) * 1996-06-14 2003-09-02 花王株式会社 Toilet cleaner composition
JPH10195498A (en) * 1996-12-27 1998-07-28 Lion Corp Liquid detergent composition
US5858939A (en) * 1997-03-21 1999-01-12 Lever Brothers Company, Division Of Conopco, Inc. Method for preparing bars comprising use of separate bar adjuvant compositions comprising benefit agent and deposition polymer
JP3025757B2 (en) * 1997-09-02 2000-03-27 花王株式会社 Disinfectant cleaning composition for floors
PL188065B1 (en) * 1997-09-12 2004-12-31 Izabella Bogacka Method of obtaining daily personal hygiene agents
BR9914502B1 (en) * 1998-10-13 2008-11-18 detergent compositions for cleaning fabrics with a cationically charged dye maintenance polymer and fabric conditioning composition.
HUP0203811A3 (en) * 1999-12-08 2005-10-28 Unilever Nv Use of polymeric material in the treatment of hard surfaces

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004075789A (en) * 2002-08-14 2004-03-11 Kao Corp Cleanser composition for hard surface
JP2004155803A (en) * 2002-11-01 2004-06-03 Kao Corp Solid cleaning agent composition for flush toilet
JP2005029756A (en) * 2003-07-11 2005-02-03 Kao Corp Detergent used for toilet
JP2005029754A (en) * 2003-07-11 2005-02-03 Kao Corp Aqueous liquid composition
WO2008054009A1 (en) 2006-10-31 2008-05-08 Kao Corporation Bleaching agent composition
JP2008133453A (en) * 2006-10-31 2008-06-12 Kao Corp Bleaching agent composition
JP2008266375A (en) * 2007-04-17 2008-11-06 Johnson Diversey Co Ltd Detergent composition for hard surface
JP2010168428A (en) * 2009-01-20 2010-08-05 Kao Corp Liquid detergent composition for hard surface
JP2011246677A (en) * 2010-05-31 2011-12-08 Ueno Fine Chem Ind Ltd Cleaning-sterilizing agent composition
JP2012092320A (en) * 2010-09-28 2012-05-17 Kobayashi Pharmaceutical Co Ltd Biofilm removing agent, composition for removing biofilm, and method for removing biofilm
JP2012111846A (en) * 2010-11-25 2012-06-14 Dainippon Jochugiku Co Ltd Acidic antibacterial detergent composition
JP2017048238A (en) * 2010-12-31 2017-03-09 バイオトロル・ピーエルシー Antimicrobial composition
JP2021008633A (en) * 2010-12-31 2021-01-28 ローディア オペレーションズ Antimicrobial composition
JP2019006832A (en) * 2010-12-31 2019-01-17 ロディア オペレーションズRhodia Operations Antimicrobial composition
JP2012193287A (en) * 2011-03-17 2012-10-11 Adeka Corp Detergent composition for oil stain
JP2012255073A (en) * 2011-06-08 2012-12-27 Kao Corp Liquid detergent composition for hard surface
JP2013023642A (en) * 2011-07-25 2013-02-04 Dainippon Jochugiku Co Ltd Rinse accelerator for hard surface detergent
JP2015507676A (en) * 2011-12-29 2015-03-12 バイオトロル・ピーエルシー Antimicrobial composition
JP2014009349A (en) * 2012-07-03 2014-01-20 Kao Corp Liquid aroma composition for flush toilet
JP2015113455A (en) * 2013-12-16 2015-06-22 花王株式会社 Sterilizing detergent composition for hard surfaces
WO2015093164A1 (en) * 2013-12-16 2015-06-25 花王株式会社 Bactericidal cleaning composition for hard surfaces
TWI615465B (en) * 2013-12-16 2018-02-21 Kao Corp Sterilizing detergent composition for hard surfaces
JP2016124965A (en) * 2014-12-26 2016-07-11 ライオン株式会社 Liquid detergent for bath room
JP2019156999A (en) * 2018-03-14 2019-09-19 株式会社ニイタカ Detergent composition, spray bottle, wet wiper, and deodorization and sterilization cleaning method
JP7075655B2 (en) 2018-03-14 2022-05-26 株式会社ニイタカ Detergent composition, spray bottle, wet wiper and deodorant disinfectant cleaning method
US10980230B2 (en) 2018-04-09 2021-04-20 Rhodia Operations Compositions and methods for long lasting disinfection
CN112203513A (en) * 2018-04-09 2021-01-08 罗地亚经营管理公司 Compositions and methods for durable disinfection
WO2019199886A1 (en) * 2018-04-09 2019-10-17 Rhodia Operations Compositions and methods for long lasting disinfection
US11877575B2 (en) 2018-04-09 2024-01-23 Rhodia Operations Compositions and methods for long lasting disinfection
JP2020041074A (en) * 2018-09-12 2020-03-19 ライオン株式会社 Liquid detergent composition for clothing
JP2020100691A (en) * 2018-12-20 2020-07-02 中国塗料株式会社 Antifouling coat composition, antifouling coat film, base material with antifouling coat film, antifouling method for base material and method for producing base material with antifouling coat film
JP7335068B2 (en) 2018-12-20 2023-08-29 中国塗料株式会社 Antifouling paint composition, antifouling coating film, substrate with antifouling coating film, antifouling method for substrate, and method for producing substrate with antifouling coating film
JP2020152856A (en) * 2019-03-22 2020-09-24 株式会社Adeka Detergent composition for rigid surface, and method of cleaning rigid surface

Also Published As

Publication number Publication date
WO2002016536A1 (en) 2002-02-28
TWI283267B (en) 2007-07-01

Similar Documents

Publication Publication Date Title
JP2002060786A (en) Germicidal stainproofing agent for hard surface
JP2003096493A (en) Germicidal antifouling detergent for rigid surface
EP1196523B1 (en) Cleansing composition comprising a water soluble or water dispersible polymer
JP5031309B2 (en) Detergent composition for dishwasher
JP4907327B2 (en) Detergent composition for dishwasher
JP4230153B2 (en) Antifouling cleaner for hard surfaces
JP3422978B2 (en) Cleaning composition for hard surfaces
JP5234701B2 (en) Cleaning composition for hard surface
JP5342126B2 (en) Bleach composition
US7544649B2 (en) Antifouling detergent for hard surfaces
JP2010047729A (en) Liquid detergent composition for dishwasher
JP5575466B2 (en) Cleaning composition for hard surface
JP3617813B2 (en) Cleaning composition for hard surface
JP4008364B2 (en) Antifouling cleaner for hard surfaces
JP2002348596A (en) Cleanser composition
JP6093280B2 (en) Liquid detergent composition for hard surfaces
JP3405970B2 (en) Cleaning composition for hard surfaces
JP3986846B2 (en) Concentrated liquid detergent for flush toilet
JP4912859B2 (en) Dishwasher finish composition
JP3558907B2 (en) Hard surface antifouling antibacterial detergent composition
JP2004155803A (en) Solid cleaning agent composition for flush toilet
JP4040326B2 (en) Concentrated liquid detergent for flush toilet
JP4732064B2 (en) Cleaning composition for hard surface
JP2002531634A (en) Safe cleaning method for enamel
JP2009275075A (en) Finishing agent composition for floor